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Abstract 
 
Background A small number of open-label or pilot studies have assessed the benefit of 
stem cell therapy in dilated cardiomyopathy (DCM). I report the findings of the 
REGENERATE-DCM trial, a double-blind, randomised, placebo-controlled trial of bone-
marrow derived mononuclear cell and adjunctive granulocyte colony stimulating factor 
(G-CSF) administration in patients with DCM. 
Methods 60 patients with DCM were randomized into four treatment groups: 
intracoronary stem cell, intracoronary serum, peripheral G-CSF and peripheral placebo 
(saline).  Apart from the placebo group, all patients received 5-days of G-CSF, with 
bone marrow harvest performed on Day 6 in the intracoronary group. Primary endpoint 
was change in left ventricular ejection fraction (LVEF) assessed by advanced cardiac 
imaging at 3 months. 
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Results There was little or no difference in baseline characteristics between the groups.  
At 3 months, intracoronary stem cell therapy was associated with a 5.37% increase in 
LVEF (38.30 ±12.97 from 32.93 ±16.46 p= 0.014).  This increase in LVEF in cell treated 
patients was associated with clear evidence of decrease in NYHA classification and 
improved exercise capacity. No evidence of a change in LVEF was seen in the other 
two treatment groups. 
Conclusion The novel combination of G-CSF and intracoronary cell therapy led to an 
improvement in cardiac function and symptoms at 3 months.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
Contents 
1. Introduction: ................................................................................................................ 87 
1.1. Dilated Cardiomyopathy ........................................................................................................................................ 87 
1.1.1. Incidence ........................................................................................................................................................................ 87 
1.1.2. Prognosis ........................................................................................................................................................................ 98 
1.1.3. Pathogenesis .............................................................................................................................................................. 109 
A- Genetic ................................................................................................................................................................................ 109 
1.1.4. Current Treatment guidelines .........................................................................................................................1917 
2. Cell therapy ...............................................................................................................2120 
2.1. Allogeneic stem cells .......................................................................................................................................... 2221 
2.1.1. Embryonic stem cells ...........................................................................................................................................2221 
2.1.2. Foetal cardiomyocytes ........................................................................................................................................2322 
2.1.3. Human umbilical cord derived stem cells ..................................................................................................2322 
2.2. Autologous cell types......................................................................................................................................... 2322 
2.2.1. Adult stem cells ......................................................................................................................................................2423 
2.2.2. Bone marrow-mononuclear cells ..................................................................................................................2423 
2.2.3. Haematopoietic stem cells ................................................................................................................................2423 
2.2.4. Mesenchymal stem cells .....................................................................................................................................2524 
2.2.5. Endothelial progenitor cells .............................................................................................................................2524 
2.2.6. Skeletal myoblasts ................................................................................................................................................2625 
2.2.7. Cardiac stem cells (cardiospheres) ...............................................................................................................2726 
2.2.8. Inducible-pluripotent stem cells (iPS) .........................................................................................................2827 
2.2.9. Thymosin Beta4 .....................................................................................................................................................2928 
2.3. Bone marrow cell (BMC) therapy in clinical trials ................................................................................ 2928 
2.3.1. BMC therapy in acute MI ...................................................................................................................................2928 
2.3.2. BMC therapy in DCM ...........................................................................................................................................3130 
3. Cytokine therapy .......................................................................................................3736 
3.1. Stem Cell mobilisation with G-CSF in humans ........................................................................................ 3736 
3.1.1. G-CSF therapy in AMI ..........................................................................................................................................3837 
3.1.2. G-CSF therapy in IHD ...........................................................................................................................................4039 
3.1.3. G-CSF therapy in DCM .........................................................................................................................................4140 
4. Clinical trial ................................................................................................................4443 
4.1.1. Rationale ...................................................................................................................................................................4443 
4.1.2. Summary of previous trials: .............................................................................................................................4443 
4.1.3. Study background and hypothesis ................................................................................................................4544 
5 
 
 
4.1.4. Study hypothesis: ...................................................................................................................................................4645 
4.1.5. Methods and study design .................................................................................................................................4746 
4.1.6. Patient population ................................................................................................................................................5150 
4.1.7. Safety endpoints and outcome measurements ........................................................................................5453 
4.1.8. Cardio-pulmonary exercise testing ...............................................................................................................5554 
5. Biomarker sub-study ..................................................................................................5756 
5.1. Background ........................................................................................................................................................... 5756 
5.2. Biomarker sub-study Hypothesis ................................................................................................................. 5857 
5.3. Brain Natriuretic Peptide ................................................................................................................................ 5857 
5.4. Randox Biochip technology ............................................................................................................................ 6160 
5.4.1. Interleukin 1α (IL-1α):........................................................................................................................................6362 
5.3.4 Interleukin 1ß (IL-1ß): .............................................................................................................................................6463 
5.4.2. Interleukin-2 (IL-2): .............................................................................................................................................6564 
5.4.3. Interleukin 4 (IL-4): .............................................................................................................................................6665 
5.4.4. Interleukin-6 (IL-6): .............................................................................................................................................6766 
5.4.5. Interleukin-8 (IL-8): .............................................................................................................................................6968 
5.4.6. Interleukin 10 (IL-10): ........................................................................................................................................6968 
5.4.7. Vascular Endothelial Growth Factor (VEGF):..........................................................................................7170 
5.4.8. Interferon- (IFN-): ............................................................................................................................................7271 
5.4.9. Epidermal Growth Factor (EGF): ..................................................................................................................7372 
5.4.10. Tumour Necrosis Factor –α (TNF-α): .......................................................................................................7473 
6. Results .......................................................................................................................7675 
6.1. Baseline characteristics .................................................................................................................................... 7675 
6.2. Primary Endpoint: Change in Ejection Fraction ..................................................................................... 8180 
6.3. LV mass, LV dimensions and stroke volume ........................................................................................... 8180 
6.4. Progenitor cell (CD34+) mobilisation with G-CSF ................................................................................. 8988 
6.5. Effect of intracoronary stem cell therapy on heart failure and    angina symptoms ............... 9694 
6.6. Change in BNP at 3 months ............................................................................................................................. 9997 
6.7. Changes in exercise functional capacity at 3 months...................................................................... 102100 
6.8. Secondary Endpoint: Quality of life ........................................................................................................ 111109 
6.9. Results of the Biomarker sub-study ....................................................................................................... 114112 
6.10. Trial Safety: .................................................................................................................................................... 121119 
7. Discussion .............................................................................................................. 123121 
8. Conclusion: ............................................................................................................ 129126 
9. Conclusions and future directions .......................................................................... 130127 
 
 
 
6 
 
 
Abbreviations 
 
DCM  Dilated cardiomyopathy 
G-CSF Granulocyte colony-stimulating factor 
GM-CSF Granulocyte-macrophage colony stimulating factor 
AMI  Acute myocardial infarction 
IHD  Ischaemic heart disease 
MI  Myocardial infarction 
CHF  Congestive heart failure 
SCF  Stem cell factor 
BMC  Bone marrow mononuclear cells 
MSC  Mesenchymal stem cells 
HSC  Haematopoietic stem cells 
EPC  Endothelial progenitor cells 
CFR  Coronary flow reserve 
LVEF Left ventricular ejection fraction 
LVSD Left ventricular systolic dysfunction 
SCF  Stem cell factor 
ISR  In-stent restenosis 
IVUS  Intravascular ultrasound 
CAD  Coronary artery disease 
NYHA New York Heart Association 
CCS  Canadian Cardiovascular Society 
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BNP  Brain-Natriuretic peptide 
RCT  Randomised controlled trial 
PCI  Percutaneous coronary intervention 
CRP  C - reactive protein 
IL-1  Interleukin-1 
IL- 1Ra  Interleukin-1 receptor antagonist 
IL-6  Interleukin-6 
IL-10  Interleukin-10 
MCP  Monocyte chemoattractant protein-1 
 
TNF-alpha Tumour necrosis factor alpha 
 
LVNC Left ventricular non-compaction 
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1. INTRODUCTION: 
1.1. Dilated Cardiomyopathy 
1.1.1. Incidence 
Dilated cardiomyopathy (DCM) is a leading cause of heart failure and remains the most 
common indication for cardiac transplantation worldwide1,2. Dilated cardiomyopathy is 
defined as the presence of depressed fractional shortening (<25%) or reduced LVEF (< 
45%), and a dilated LV (end-diastolic diameter of > 117% of the corrected predicted 
value)3, in the absence of coronary artery disease or abnormal loading conditions (such 
as hypertension or valve disease) sufficient to cause global systolic impairment4. Right 
ventricular dysfunction and dilation may be present but are not necessary for the 
diagnosis.  The estimated incidence of DCM in North American and European 
populations is estimated at 6-8 per 100,0005,6 and the prevalence at 36.5 per 100,0005. 
It remains a leading cause of heart failure under the age of 35 and the most common 
indication for cardiac transplantation worldwide1,2. The reported frequencies probably 
represent an underestimate, however, since most studies focus on index cases 
presenting with clinical heart failure.  A primary diagnosis of heart failure represents 1% 
of all inpatient cases in men and 0.4% in women. The average length of stay for a 
patient admitted to hospital with heart failure is over 13 days, three times the average 
length of stay for all patients. In the last ten years, the number of hospital admissions for 
heart failure in England has increased by around 5% in men and 4% in women aged 45 
years and over. In England, hospital admissions for heart failure are projected to 
increase by over 50% over the next 25 years, from 74,500 in 2000/01 to 113,000 in 
2026/27. 
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Previously, the majority of patients in any DCM cohort presented with symptoms of high 
pulmonary venous pressure and a low cardiac output. Increasingly, DCM is diagnosed 
as an incidental finding in asymptomatic individuals during routine examination or family 
screening7-9. Heart failure occurs as a consequence of continuous neurohormonal 
stimulation, which results in arteriolar vasoconstriction, sodium and water retention, 
endothelial dysfunction and fibrosis. In index cases, the diagnosis of DCM is made in 
the presence of depressed fractional shortening (<25%) or reduced LVEF (< 45%), and 
a dilated LV (end-diastolic diameter of > 117% of the corrected predicted value)3.  
1.1.2. Prognosis 
The prognosis of DCM is highly variable. Earlier studies reported 5-year mortality rates 
of 50%, which have declined to 20% in more recent reports. This improvement in 
survival reflects both early disease detection and advances in heart failure therapy. 
However the prognosis and quality of life in symptomatic heart failure patients remains 
worse than many malignancies and serious chronic conditions such as arthritis and 
chronic lung disease10.   
Prognostic markers of increased mortality in DCM include the degree of LV dysfunction, 
higher NYHA functional class and high Brain-natriuretic peptide (BNP) levels. BNP is a 
powerful predictor of all cause mortality in heart failure11 and may also predict the 
response to therapy12. Patients with DCM may have impaired coronary flow reserve 
(CFR) and microvascular obstruction13 despite normal epicardial coronary arteries. 
Impaired CFR is also associated with an increase in mortality and progression of heart 
failure14. 
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1.1.3. Pathogenesis 
A- Genetic 
Over 40 disease causing genes have been identified to date15,16 most of which encode 
proteins of the sarcolemma17-19, cytoskeleton20, sarcomere21-24, nuclear envelope (e.g. 
Lamin25-27) and energy generation28 (Table 1).  The structural and functional 
consequences of mutations in cytoskeleton, sarcomere, sarcolemma and nuclear 
envelope include impairment of myocardial force generation, force transmission and cell 
survival (figure 1). DCM is inherited as an autosomal dominant trait in 90% of families. 
This mode of transmission is often associated with incomplete and age-related 
penetrance, although onset by the fourth decade of life is typical9. Expression is also 
variable and frequently incomplete; although symptomatic disease may not be present, 
cardiac evaluation may reveal unexplained ECG and/or echocardiographic 
abnormalities. Autosomal dominant forms of DCM may be associated with conduction 
disease29 or skeletal myopathy30,31. 
Other modes of inheritance include autosomal recessive, X-linked recessive, and 
mitochondrial. In autosomal recessive DCM, patients usually present at a younger age 
compared with the autosomal dominant form. The disease course is characterised by 
more rapid progression to death or cardiac transplantation9. X-linked inheritance is 
characterised by the absence of male to male transmission4,9. Women may be affected 
but usually express a milder form of disease expression and are affected at an older 
age. Affected patients usually, but not always, have an increase in CK (MM) isoform 
level, e.g. mutations in dystrophin which also cause Duchenne and Beckers muscular 
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dystrophy. Matrilineal inheritance is usually associated with signs of mitochondrial-
related phenotype such as lactacidaemia, hypoacusia, palpebral ptosis, myopathy with 
ragged red fibres, ophtalmoplegia, encephalopathy, or retinitis pigmentosa. In this form 
of inheritance the mother, son or daughter may be affected, but the affected males do 
not transmit the disease to their offspring.  
Incomplete phenotypic expression is common among relatives of subjects with DCM, 
contributing to under-recognition of familial disease. Nevertheless, nearly a third of 
asymptomatic relatives of patients with DCM have echocardiographic abnormalities on 
screening (such as depressed fractional shortening and left ventricular enlargement), 
and over a quarter of these patients develop overt DCM7. Furthermore, cardiac specific 
autoantibodies were present in over 30% of asymptomatic relatives of patients with 
DCM32,33, and are weak independent predictors of developing DCM at 5 year follow-
up33,34. In a longitudinal study of families with DCM, 23% of 767 asymptomatic relatives 
were found to have echocardiographic evidence of depressed fractional shortening or 
LV dilation, and these patients were 8 times more likely to develop overt DCM than 
those with normal echocardiograms35.  Additional studies in the asymptomatic relatives 
revealed that the 25% of relatives with LV enlargement without systolic dysfunction had 
histological findings consistent with DCM36 and had a significant reduction in exercise 
capacity7,37. This suggests that LVE represents subclinical disease, with incomplete 
penetrance. In spite of low penetrance, incomplete and variable expression, and small 
nuclear families commonly evaluated in clinical practice, familial disease can be 
confirmed in up to 50% of DCM cases. 
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Figure 1: The structure of the cardiac myocyte, showing the sarcomere, the cytoskeletal 
network, calcium channels, nuclear proteins, lysosomes, mitochondria, and AMP-
activated protein kinase (AMPK). Mutations in the genes encoding most of the protein 
components of these structures lead to cardiomyopathies (reproduced from Arnous et al 
Genetics of Dilated Cardiomyopathy: Risk of Conduction Defects and Sudden Cardiac Death; 
cardiac electropyshiology,2010 15).  
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Table 1: Gene mutations associated with dilated cardiomyopathy 
Protein Gene Locus Mode of 
Transmission 
Associated 
phenotype 
References 
Sarcomeric      
Actin ACTC 15q14 AD None 21 
α-tropomyosin TPM1 15q22 AD None 21 
β-myosin heavy 
chain 
MYH7 14q12 AD None 22,38-40 
α-myosin heavy 
chain 
MYH6 14q12 AD None 41 
Troponin T TNNT2 1q32 AD None 22,24,42 
Troponin C TNNC1 3p21-p14 AD None 24 
Troponin I TNNI3 19q13 AD, AR None 43,44 
Myosin-binding-
protein-C 
MYBPC3 11p11 AD None 45 
Sarcomere and Z-disc 
related 
     
Titin TTN 2q31 AD None 46 
Telethonin TCAP 17q12 AD None 47,48 
Muscle LIM protein CSRP3 11p15 AD None 47 
Metavinculin VCL 10q22-q23 AD None 49 
Cypher/ZASP LDB3 10q22-q23 AD CD, LVNC 50 
α-Actinin 2 ACTN2 1q42-q43 AD None 51 
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Table 1: Gene mutations associated with dilated cardiomyopathy (continued) 
 
Protein Gene Locus Mode of 
Transmission 
Associated 
phenotype 
References 
PDZ and LIM 
domain  
Protein 3 
PDLIM3 4q35 AD None 52 
Myopallidin MYPN 10q21 AD None 53 
Four-and-a-half LIM 
protein 2 
FHL2 2q12-q14 AD None 54 
Nexilin NEXN 1p31 AD None 55 
Cytoskeletal      
Desmin DES 2q35 AD CD, SM 20,56 
Dystrophin DMD Xp21 XLR SM 19,57 
δ-sarcoglycan SGCD 5q33 AD SD 17 
αß-Crystallin CRYAB 11q22-q23 AD None 58 
Nuclear      
Lamin A/C LMNA 1q21 AD CD, SD, SM 25,26,31,59-64 
Thymopoeitin TMPO 12q22 AD# None 65 
Emerin STA/EMD Xq28 XLR Emery-Dreifuss 
muscular 
dystrophy 
66 
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Table 1: Gene mutations associated with dilated cardiomyopathy (continued) 
 
Protein Gene Locus Mode of 
Transmission 
Associated 
phenotype 
References 
Ion channel and ion 
channel related 
     
Sulphonylurea 
receptor-2 (SUR2) 
ABCC9 12p12.1 AD None 67 
Desmosomal      
Desmoplakin DSP 6p24 AR Carvajal 
syndrome 
68 
Other      
Phospholamban PLN 6q22 AD None 69-71 
Tafazzin TAZ/G4.5 Xq28 XLR Neutropenia, 
Short stature 
72 
M2 muscarinic 
receptor 
CHRM2 7q35 AD# CD, SD 73 
Eya4 EYA4 6q23 AD# SHL 74 
LAMP2 LAMP2 Xq24 AD# CD, SM 75 
Laminin -α4 LAMA4 6q21 AD# None 76 
Integrin-linked 
kinase 
ILK 11p15 AD# None 76 
Presenilin 1 PSEN1 14q24 AD# None 77 
Presenilin 2 PSEN2 1q31-q42 AD# None 77 
Cardiac ankyrin 
repeat protein 
(CARP) 
ANKRD1 10q23 AD None 78 
RNA binding motif  
protein 20 
RBM20 10q25 AD None 79 
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B- Acquired 
A list of acquired causes of dilated cardiomyopathy and putative mechanisms of action 
is summarised in table 2. 
 
1- Viral cardiomyopathy – viral infection can cause myocarditis and 
cardiomyopathy via a direct cytotoxic effect on the myocardium, or an adverse 
autoimmune response due to persistent viraemia. Causative agents include 
Coxackie B, influenza virus and human immunodeficiency virus (HIV). 
2- Alcohol – excessive alcohol consumption can lead to cardiomyopathy in 
susceptible individuals. Although the exact proposed mechanism is unknown, 
alcohol is thought to cause myocardial dysfunction via oxygen free radicals and 
defects in cardiac protein synthesis. Abstinence can often lead to dramatic 
improvement in cardiac function. 
3- Peripartum cardiomyopathy – This is a rare cause of cardiomyopathy that 
occurs in late pregnancy and within the first 5 months of the postpartum period, 
and is strongly associated with gestational hypertension and twin pregnancy4. 
Prognosis depends on the degree of LV dysfunction at the time of diagnosis. 
Even if patients recover, there is a risk of recurrence in subsequent pregnancies 
so patients are advised against further pregnancies.  
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4- Medications – The most common medications implicated in cardiomyopathy 
include anthracycline, doxorubicin, adramyacin and cyclophosphamide. Other 
drugs associated with DCM include antiretroviral agents (Lamivudine), 
antipsychotics (clozapine), and antidepressants (amitriptyline and 
clomipramine)80. 
 
4-5- Left ventricular non-compaction  
Left ventricular non-compaction (LVNC) is a disorder of the myocardium defined by the 
presence of prominent trabeculations on the luminal surface of the left ventricle and the 
presence of deep inter-trabecular recesses that extend into the ventricular wall81. 
Diagnosis of LVNC can be difficult as fine trabeculations are a feature of the normal 
ventricle. However recent advances in imaging modalities such contrast 
echocardiography and cardiac magnetic resonance imaging (MRI) have lead to an 
improvement in visualising the trabeculations. Patients with LVNC often have an 
associated dilated cardiomyopathy and present with symptoms of systolic heart failure. 
Management of the heart failure is no different to that in DCM. 
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Table 2: Acquired causes of DCM and putative mechanism of disease 
 
 
AETIOLOGIES OF DCM PUTATIVE MECHANISM OF DISEASE 
VIRAL INFECTION (COXSACKIE B, INFLUENZA, HIV) 
 
CHRONIC INFLAMMATION, VIRAL PROTEIN PERSISTENCE 
 
PREGNANCY 
 
MYOCARDITIS, AUTOIMMUNE 
 
METABOLIC DISORDERS (HAEMOCHROMATOSIS) 
 
IRON DEPOSITION, MYOCYTE DYSFUNCTION. 
EOSINOPHILIC (CHURG STRAUSS SYNDROME) 
 
EOSINOPHILIC ENDOMYOCARDITIS, INTERSTITIAL FIBROSIS 
KAWASAKI DISEASE 
 
CORONARY ANEURYSM AND RECURRENT THROMBO-EMBOLI 
ALCOHOL 
 
DIRECT TOXIC EFFECT ON THE MYOCARDIUM 
ENDOCRINE (HYPOPHOSPHETAEMIA, 
HYPOCALCAEMIA, THIAMINE) 
 
IMPAIRMENT OF MYOCARDIAL CONTRACTILITY 
DRUGS (DOXORUBICIN, ADRIAMYCIN, 
CYCLOPHOSPHAMIDE) 
 
FREE RADICALS AND INCREASED OXIDATIVE STRESS 
 Tachycardia induced 
cardiomyopathy 
Left ventricular remodelling, dilation and 
electrical disturbances 
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1.1.4. Current Treatment guidelines 
 Dilated cardiomyopathy represents the final common morphologic outcome of various 
biologic insults resulting in myocardial necrosis and chronic fibrosis. The proposed 
mechanisms involved in the pathogenesis of DCM include genetic predisposition, viral 
infection, myocardial ischemia and antibody-mediated cytotoxicity and apoptosis of 
cardiomyocytes. Currently patients with DCM are treated in accordance with the 
European Society of Cardiology (ESC) guidelines for the management of heart failure, 
which are backed by clinical trials82 (Table 3). There remains, however, a significant 
knowledge gap. The optimal approach to forestalling progression in relatives with early 
disease is unresolved. Furthermore, there is an unmet need to individualise standard 
therapies, which do not factor in the influence of underlying aetiology on treatment 
responsiveness. Recent studies suggest that this might result in sub-optimal or 
inappropriate therapy in some patients83-85. Furthermore, current conventional therapies 
in DCM do not correct the underlying defects in cardiac muscle. The only therapeutic 
option that currently addresses fibrosis and cardiomyocyte loss is heart transplantation. 
Heart transplantation has a significant impact on mortality with a survival rate following a 
heart transplant of 83% at 1 year and 72% at 5 years86. However, due to stringent 
selection criteria and chronic shortage of donor hearts, the vast majority of patients are 
deemed unsuitable or never receive a transplant. Left ventricular assist device (LVAD) 
has been shown to improve the short-term survival as a bridge to transplantation or in 
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patients who are not suitable for cardiac transplant87,88. However there are many 
limitations to LVAD including the risk of stroke, device infection and device failure87,88. 
Therefore, preventing this progression of myocardial dysfunction is a major challenge 
requiring novel therapeutic strategies, such as stem cell transplantation, to improve the 
prognosis and quality of life for these patients. 
 
Table 3: Pharmacological therapy in systolic heart failure 
Pharmacological agent Effect  
Angiotensin Converting Enzyme Inhibitors  
(ACEIs) 
Improves mortality, symptoms, exercise 
tolerance, quality of life, and exercise 
performance89. 
ß-Blockers 
Improves ventricular function and patient well-
being, reduces hospital admission, and 
increases survival90. 
Aldosterone Antagonists 
Reduce hospital admission and improve 
survival91. 
Digoxin 
No effect on survival. Improves ventricular 
function and patient well-being, reduces 
hospital admission92. 
Diuretics 
Improve symptoms and relief pulmonary and 
venous congestion93. 
LCZ696 angiotensin II receptor blocker and 
neprilysin  
More effective in reducing the risk of death 
from cardiovascular causes or hospitalization 
for heart failure than was ACE inhibition with 
enalapril94 
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2.  CELL THERAPY 
The human hearts own self-renewal capabilities are unable to overcome the massive 
loss of cardiomyocytes, up to one billion cells, seen in acute myocardial infarction and 
heart failure. Regenerative medicine is an emerging interdisciplinary field of research, 
which hopes to use the properties of embryonic stem cells and adult stem cells in 
clinical applications focusing on the repair and regeneration of cells, tissues, or organs. 
One of the many remaining unanswered questions is which type of stem/progenitor cell 
is the best candidate for cardiac regeneration.  Stem cells are defined by two unique 
characteristics: they are unspecialized cells capable of unlimited self-renewal, and they 
can differentiate into more specialized cells and organs.  
 
Stem cells can be broadly divided into those that are derived from the embryo 
(embryonic stem cells - ESCs) and those that are found in adult tissue (adult stem 
cells). ESCs are pluripotent, which means having the ability to develop into cells from all 
three germinal layers (i.e., mesoderm, endoderm and ectoderm) and produce all the 
tissue types needed to form a functional organism. Developed adult organs also contain 
undifferentiated stem cells but in far fewer numbers: these are called adult (somatic) 
stem cells (ASC). These cells were thought to be limited in differentiation potential and 
only able to replenish and repair injured tissue in the organ in which they resided. 
Stem cells can be further divided according to the number of differentiated cell types 
they can produce95.   
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1- Totipotent: Cells able to form all fully differentiated cells of the body and 
trophoblastic cells of the placenta. The only cells considered to be totipotent are 
the embryo, zygote and the descendants of the first two cell divisions. 
2- Pluripotent: Cells able to differentiate into almost all cells that arise from the 
three germ layers. They are unable to give rise to placental cells. An example of 
pluripotent cells is embryonic cells that form the inner cell mass of the blastocyst. 
These cells are formed at around 5 days following fertilisation.  
3- Multipotent: For example adult stem cells are capable of forming a limited range 
of differentiated cell lineages.  
2.1. Allogeneic stem cells 
2.1.1. Embryonic stem cells 
Embryonic stem cells (ES), the most primitive of stem cells, are derived from the inner 
cell mass.  ES are pluripotent, meaning that they are able to transform into any type of 
cell including cardiomyocytes and can replicate indefinitely95. However ethical issues, 
their potential to form teratomas and the need for immunosuppressive therapy have 
hindered their use in clinical trials. 
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2.1.2. Foetal cardiomyocytes 
Foetal cardiomyocytes were one of the first cell types to be investigated as potential 
candidates for cardiac repair. However, the use of fetal cardiomyocytes has similar 
concerns to ESCs, including availability, immunogenicity, and ethics. 
2.1.3. Human umbilical cord derived stem cells 
Umbilical cord blood is blood which remains in the placenta and in the attached 
umbilical cord after childbirth. It has been shown to be a potent source of hematopoietic 
stem cells. Cord blood contains a large number of non-hematopoietic stem cells which 
rarely express HLA class II antigens and appear to be immunologically naive, thus 
reducing the risk of rejection. In animal models of acute myocardial infarction, injection 
of human umbilical cord blood mononuclear cells is associated with significant 
reductions in infarct size.  
 
2.2. Autologous cell types 
A number of adult cell types have been shown to induce cardiac repair or functional 
improvement. These include bone marrow derived mononuclear cells (BMCs) that 
consist of haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and 
endothelial progenitor cells (EPCs). Other adult derived progenitor cells that have been 
extensively investigated for regenerative capacity include skeletal myoblasts, cardiac 
resident stem cells, umbilical cord blood stem cells and inducible pluripotent stem cells.  
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2.2.1.  Adult stem cells 
Adult stem cells are present in already developed tissue. They are an attractive option 
to explore for transplantation as they are autologous, but their differentiation potential is 
more restricted than embryonic stem cells. They are multipotent, which means they can 
only differentiate into a limited range of cell types. They can transdifferentiate into 
specialised cells that are outside their lineage commitment96. Adult stem cells are 
divided into the following depending upon their origin: 
2.2.2. Bone marrow-mononuclear cells 
Currently, the major sources of adult cells used for basic research and in clinical trials 
originate from the bone marrow. The bone marrow mononuclear subset is 
heterogeneous and comprises mesenchymal stem cells, haematopoietic progenitor 
cells and endothelial progenitor cells. The differentiation capacity of different 
populations of bone marrow-derived stem cells into cardiomyocytes has been studied 
intensively. 
2.2.3. Haematopoietic stem cells 
Haematopoietic stem cells (HSC) are defined as cells that transdifferentiate along the 
blood lineage. They do not have the ability to transdifferentiate into cardiomyocytes in 
vitro. However, in a mouse model, treatment with Granulocyte colony stimulating factor 
(G-CSF) and stem cell factor (SCF) after a myocardial infarction enhanced the 
mobilisation and homing of HSC from the bone marrow. This led to cardiomyogenesis 
and vasculogenesis and an improvement in survival and cardiac function97. In contrast, 
in non-human primate models, infusion of G-CSF and SCF post MI was not associated 
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with cardiomyogenesis or improvement in LV function but did promote angiogenesis98. 
The first human trial was conducted on patients with severe CAD not amenable to 
coronary artery bypass. The authors demonstrated an improvement in collateral flow 
with short -term administration of Granulocyte-macrophage colony stimulating factor 
(GM-CSF). More studies are needed to assess the beneficial effect of HSC mobilisation 
on cardiac regeneration. 
2.2.4. Mesenchymal stem cells 
Mesenchymal stem cells (MSC) are ubiquitous in various tissues including bone 
marrow, skin, adipose tissue and muscle. They have the potential to differentiate into 
cells and tissue of mesenchymal origin including muscle, bone, cartilage and adipose 
tissue. Unlike haematopoietic progenitor cells, MSC are negative for CD34 and CD45 
and they stain positively for cardiac, endothelial specific markers and gap junction 
proteins. MSC can transdifferentiate into cardiomyocytes and endothelial cells in vivo 
when transplanted into the heart in MI models99, and in the setting of dilated 
cardiomyopathy their transplantation in animal models has been shown to improve 
cardiac function100. Their regenerative potential and ability to facilitate myocardial and 
vascular repair make them an attractive option for regenerative cell therapy, however 
further research is needed to provide a better understanding into their basic physiology 
and therapeutic potential. 
2.2.5. Endothelial progenitor cells 
Endothelial progenitor cell (EPCs) are derived from the bone marrow or the peripheral 
circulation (CEPCs) and play an important role in vasculogenesis in myocardial 
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infarction and limb ischemia. EPCs and CEPCs differ phenotypically and functionally 
from mature endothelial cells by expressing the marker AC133101,102. AC133 is 
expressed on cells with pluripotent stem cell properties. In animal models of MI, 
transplantation of EPCs or CEPCs causes a significant increase in capillary density, 
regional blood flow and cardiac function in the ischaemic heart103,104. This improvement 
in cardiac function has been translated in small non-randomised controlled human trials. 
Transplantation of EPC or CEPCs in the setting of acute MI or ischaemic 
cardiomyopathy has led to an increase in cardiac function (improvement in EF by 7-9%) 
and improvement in myocardial perfusion105-110. 
2.2.6. Skeletal myoblasts 
Skeletal myoblasts (also called satellite cells) form a reservoir of regenerative cells 
located at the basal lamina of skeletal muscle tissue. These cells were one of the first to 
be used for regenerative cell therapy in cardiac disease. They have a high potential for 
self renewal after muscle injury. Their high resistance to ischemia and ability to survive 
in an environment with poor vascularisation has made skeletal myoblasts an attractive 
option for cardiac repair. One of the major characteristics of skeletal myoblasts is that 
they are committed to the myogenic lineage and therefore when engrafted into infarcted 
myocardium they do not electrically couple with cardiomyocytes or express 
cardiomyocytes specific markers. On the one hand this lineage restriction provides a 
reassuring safe guard against tumour formation; however it also prevents the myogenic 
cells to differentiate into cardiomyocytes. Since myoblasts do not readily 
transdifferentiate into a new generation of cardiac cells, it is likely that they exert their 
beneficial effect on the LV through their contractile properties and paracrine effects.    
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Preclinical animal studies have demonstrated that, after transplantation into infarcted 
myocardium, skeletal myoblasts form myotubules and enhance cardiac function111.  A 
preliminary clinical trial demonstrated that engraftment of myoblasts into the heart is 
feasible and is associated with an improvement in LV function112. However the increase 
in the incidence of ventricular tachycardia and life-threatening arrhythmias in early 
studies halted their use in clinical trials113. This observation made the prophylactic use 
of implantable cardioverter-defibrillator mandatory before conducting further clinical 
trials using skeletal myoblasts. However in the largest randomised controlled trial to 
date (the MAGIC trial)114, an internal cardioverter defibrillator was implanted in every 
patient in the treatment and placebo group. This did not reveal a significant difference in 
the incidence of arrhythmias between the two groups. However there was no significant 
improvement in LV function between the 2 groups. Skeletal myoblasts cannot as yet be 
used as an established cell therapy due to their inability to transdifferentiate into 
cardiomyocytes, and lack of evidence on the beneficial effect on LV function. 
 
2.2.7. Cardiac stem cells (cardiospheres) 
Until recently the accepted paradigm was that the human heart is a post mitotic and 
terminally differentiated organ and the only adaptive response to cellular injury is 
myocardial hypertrophy. A study examining hearts post myocardial infarction indicated 
that a subpopulation of myocytes was not terminally differentiated and the number of 
dividing myocytes was significantly larger in the peri-infarct zone than in the distant 
myocardium115.  The presence of Lin⁻ C-Kit⁺  cells with myogenic stem cell properties 
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within the rat myocardium suggests that the heart contains stem cells with regenerative 
capacity116. These cells gave rise to myocytes, smooth muscle and endothelial vascular 
cells when injected into an ischemic heart. The injected cells regenerated 50% of the 
contractile myocytes normally present in the myocardium in a matter of few weeks. This 
has raised the exciting possibility that these cells can be coached to home on the 
infarcted or fibrosed myocardium in vivo and promote functional recovery without the 
need for introducing exogenous cells. Several clinical trials are underway examining the 
safety and efficacy of autologous cardiac stem cells and their effect on cardiac repair 
and clinical outcome. 
2.2.8. Inducible-pluripotent stem cells (iPS) 
Cells that more closely resemble embryonic stem cells in their regenerative potential 
without the ethical issues would ultimately provide an important future direction. A cell 
type that comes close, and is on the horizon of being tested for potential clinical 
application, is the inducible pluripotent stem cells (iPS). iPS can be reprogrammed back 
to an undifferentiated pluripotent state by inserting four genes, Oct3/4, Sox2, KL4 and c-
Myc, into differentiated somatic cells similar to ES in morphology, proliferation and 
teratomas formation117-119. The biggest obstacles preventing iPS cells from hitherto 
being used in clinical trials are the difficulty to produce sufficient cells for clinical use and 
their ability to form cancer cells. Tumour formation potential is due to the fact that iPS 
cell lines are derived by inserting putative oncogenes using integrating retroviruses into 
the host genome. A study suggested that up to 20% of the iPS cell offspring developed 
tumours120. These issues need to be overcome before iPS cells can be used in clinical 
trials. Until then, it is important to establish whether the simple unfractionated bone 
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marrow cell approach has a clinical benefit, given the large number of studies that have 
been performed using this cell type without providing a clear answer.  
2.2.9. Thymosin Beta4 
Thymosin Beta4 is a G-actin monomer binding protein (a peptide) that plays an 
important role in protection, regeneration and remodelling of injured tissues. It has the 
ability to minimize myocardial loss after a MI121. The epicardium is a protective layer of 
connective tissue that covers the heart and delivers signals that can induce the growth 
of foetal cardiac muscle and coronary vessels that migrate into the myocardium. 
Treatment with Thymosin Beta4 has been shown to induce adult embryonic epicardial 
cells to form vascular precursors for angiogenesis and vasculogenesis122,123. A recent 
study showed that pre-treatment with Thymosin Beta4 in mice for 7 days prior to MI 
activated the resident epicardial stem cells124. This resulted in a significant improvement 
in ejection fraction (EF) at 28 days post infarction (mean EF 23% in placebo arm vs. 
41% in treatment arm). There was also a reduction in end systolic and diastolic 
diameters and a reduction in infarct size. Although this has generated a lot of 
excitement, methods of optimising the efficiency of Thymosin Beta4 will need to be 
established before this resident progenitor cell based therapy becomes a realistic option 
in humans. 
2.3.  Bone marrow cell (BMC) therapy in clinical trials 
2.3.1. BMC therapy in acute MI 
A landmark animal study by Orlic et al demonstrated that intramyocardial injection of 
bone marrow derived stem cells (BMC) after acute MI in murine models led to 
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cardiomyogenesis and neoangiogenesis resulting in a significant recovery of the 
myocardium125.  Since then numerous animal studies using stem cell transplantation in 
acute and chronic myocardial ischemia demonstrated improvements in cardiac function 
and reduction in infarct size126. This led to various clinical trials assessing the effect of 
BMC on cardiac function post myocardial infarction (table 4).    
A comprehensive systematic review which included 13 trials with a total of 811 
patients, showed an improvement in LVEF by 2.99% in the BMC group compared to 
standard reperfusion therapy127. A previous met-analysis by Lipinski et al which 
included 10 trials with AMI, showed that intracoronary stem cell therapy (within the first 
14 days after infarction) was associated with a small but significant (3.0%) 
improvement in LV systolic function compared to standard medical therapy128. It was 
also associated with a non-significant reduction in death and rehospitalisation from 
heart failure. Although they found no significant association between the benefits of 
intracoronary cell injection and the number of injected cells, there was a trend toward a 
statistically significant association with the injected volume, suggesting the possible 
presence of a dose-response relationship. The improvement in LVEF was observed in 
both bone marrow and peripheral mononuclear cells. Similar conclusions were 
reached in the meta-analysis by Abdel-Latif et al, which included 18 studies and 
showed that stem cell therapy significantly increased LVEF by 3.66%129.  
In contrast to animal models, the improvement in LV function in most clinical trials is at 
best modest. However these end points were used as surrogate markers looking for any 
evidence of efficacy 
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It should also be noted that several of our established therapies that have an impact on 
prognosis in patients with MI and a reduced LV function, such as angiotensin-
converting enzyme (ACE) inhibitors, β-blockers130, thrombolytic therapy and 
percutaneous coronary intervention131,132, are associated with similar improvements in 
LVEF. It is likely that adult stem cells exert their benefit on cardiac remodelling through 
an ‘indirect’ paracrine effect, and that the small functional benefit seen with this therapy 
may translate into significant long term improvement in exercise tolerance and 
survival133. 
The main surrogate markers used as an end-point have been ejection fraction and 
perfusion defects, which correlate poorly with prognosis and quality of life134,135. 
Therefore, in the future, the validation of progenitor cell therapy for clinical use may 
depend on the demonstration of a benefit with regard to clinical outcomes such as 
improvement in prognosis, quality of life136, NYHA functional class and exercise 
capacity.  
 
2.3.2. BMC therapy in DCM 
Intramyocardial injection of BMC in animal studies was associated with enhanced LV 
remodelling and an improvement in survival137, as well as induction of angiogenesis and 
inhibition of myocardial fibrosis100.  
Promising results from these animal studies in DCM led to the publication of small pilot 
studies showing that stem cell transplantation led to an improvement in cardiac function, 
symptoms and ventricular remodelling after intramyocardial and intracoronary 
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injection138-141 (Table 5). A pilot study of intracoronary stem cell implantation in patients 
with DCM showed a significant improvement in ejection fraction by 5.4% and an 
improvement in NYHA functional class in the treatment group at 6 month follow-up142. A 
case report of intracoronary injection of autologous bone marrow progenitor cells 
resulted in a reduction of NYHA class from IV to I, an improvement of EF from 20% to 
45% and a significant reduction in plasma BNP levels at 6 month follow-up143. In the 
TOPCARE-DCM trial, intracoronary administration of BMC was associated with regional 
and global improvement in LVEF at 3 month follow-up, associated with an improvement 
in microvascular function144. More recently, a pilot randomised trial showed that 
intracoronary delivery of autologous CD34+ cells improved left ventricular function and 
exercise tolerance and potentially improved survival145. Although the results of these 
studies are encouraging, it is difficult to draw any conclusive evidence regarding the 
efficacy of stem cell therapy as most of these trials were not randomised and did not 
include a control group. Therefore, there is clearly a need for large randomised trials to 
address the efficacy of stem cell therapy in heart failure secondary to DCM, and to 
provide a better understanding of the various unanswered questions with this novel 
therapy.  
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Table 4 Clinical trials of BMC therapy in acute myocardial infarction 
Study 
reference 
Study 
design 
N Timing 
post 
infarction 
Adjunct 
procedure 
Outcome 
Meluzin et al146 
(2006) 
RCT 66 5-9 days PCI Dose 
dependent 
Improvement 
of regional 
myocardial 
function by 
PET 
Fernandez-
Aviles et al108 
(2004) 
Pilot  20 13.5±5.5 
days 
PCI Decrease in 
end systolic 
volume, 
improvement 
in regional 
and global LV 
function 
Janssens et 
al147 
(2006) 
RCT 69 1 day PCI No effect on 
global LVEF, 
but may 
favourably 
affect infarct 
remodelling 
Lunde et al148 
(2006) 
RCT 97 6 days PCI No effect on 
global LVEF 
Schächinger et 
al149 
(2006) 
RCT 204 3-7 days PCI Improvement 
in global 
LVEF 
  
34 
 
 
Table 4 Clinical trials of BMC therapy in acute myocardial infarction (continued) 
Study 
reference 
Study 
design 
N Timing 
post 
infarction 
Adjunct 
procedure 
Outcome 
Ge J et al150 
(2006) 
RCT 20 Immediate
ly  
PCI Improvement 
in LVEF 
De Lezo JS et 
al151 
(2007) 
RCT 30 7 days IV 
fibrinolytics 
+PCI 
Improvement 
in LVEF 
Wollert et al110 
(2004) 
RCT 60 4.8 days PCI Improvement 
in LV systolic 
function 
Lipiec et al152 
(2009) 
Pilot  39 4-11 days PCI Improvement 
in myocardial 
perfusion 
with no effect 
on global 
LVEF 
Huikuri et al153 
(2008) 
RCT 80 2-6 days IV 
thrombolysi
s + PCI 
Improvement 
in global 
LVEF 
Assmus et al105 
(2002) 
Pilot  59 3-7 days PCI Improvement 
in LVEF 
Schächinger et 
al109 
(2004) 
Pilot  59 3-7 days PCI Improvement 
in EF 
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Study 
reference 
Study 
design 
n Timing 
post 
infarction 
Adjunct 
procedure 
Outcome 
Table 4 Clinical trials of BMC therapy in acute myocardial infarction (continued) 
Study 
reference 
Study 
design 
N Timing 
post 
infarction 
Adjunct 
procedure 
Outcome 
Strauer et a154l 
(2002) 
Pilot  20 5-9 days PCI Reduction in 
infarct region 
Bartunek et 
al155 
(2005) 
 
Pilot 35 11.6 days PCI Improvement  
in LVEF 
Hirsch et al156 
(2010) 
 
RCT 200 3-8 days PCI No effect on 
global or 
regional LV 
function 
Kuethe et al157 
(2004) 
Pilot  5 6 days PCI No 
improvement 
in LV function 
Penicka et al158 
(2007) 
Pilot 27 9 days PCI No 
improvement 
in LV function 
  
RCT; randomised controlled trial, PCI; percutaneous coronary intervention, LV; left 
ventricular, LVEF; left ventricular ejection fraction. 
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Table 5 Summary of pilot studies of BMC therapy in dilated cardiomyopathy 
 
 
 
 
Study  Patient 
number  
Type of Study Route of 
Delivery  
Outcome  Ref  
Arguero et al 
(2006) 
5 Pilot I.M via 
thoracotomy 
Improvement in 
LV function and 
NYHA 
139 
Ghodsizad et 
al (2006) 
1 Case report I.M minimally 
invasive trans 
epimyocardial 
Improvement in 
LV function 
138 
Seth et al 
(2006) 
24 Pilot I.C Improvement in 
LV function and 
NYHA 
142 
Fischer-
Rasokat et al 
(2009) 
33 Pilot I.C Improvement in 
LV function and 
microvascular 
function 
14446 
Vrtovec et al 
(2011) 
55 Pilot I.C Improvement in 
LV function and 
exercise tolerance  
145 
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3. CYTOKINE THERAPY  
Endogenous G-CSF is a potent haematopoietic cytokine that affects progenitor cell 
proliferation, maturation and functional activation159 and enhances the mobilisation and 
recruitment of stem cells from the bone marrow to the circulation160. Stem cells could be 
mobilised from the bone marrow in mouse models of myocardial infarction using a 
combination of the cytokines stem cell factor (SCF) and granulocyte colony stimulating 
factor (G-CSF)97.Treatment with these cytokines for 5 days prior to coronary artery 
ligation and for 3 days afterwards resulted in reduction in mortality, infarct size, and an 
improvement in left ventricular function. 
3.1. Stem Cell mobilisation with G-CSF in humans 
 
G-CSF produced by recombinant DNA technology has historically been used to treat 
chemotherapy-induced myelosuppression. Recently the cytokine has been used for 
treatment of post-transplantation neutropenia, chronic severe congenital or acquired 
neutropenia, and mobilization of haematopoietic progenitor stem cells into the 
circulation for collection by leukapheresis. Determination of the concentration of cells 
expressing the CD34 cell surface protein in the peripheral blood by flow cytometry is 
accepted as an accurate marker of stem cell mobilization. With a standard G-CSF dose 
of 10 μg/kg/day given subcutaneously for 5 days, at least a 10-fold increase in 
circulating CD34+ cells, a population that contains long-term repopulating stem cells, 
can be achieved. The majority of CD34+ cells are lineage-committed haematopoietic 
precursor cells, but stem cells with multi-lineage engraftment abilities are mobilised 
concurrently. In this regard, multiple studies have documented a close relationship 
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between the quantity of CD34+ cells administered to patients, whose own marrow has 
been ablated, and the rapidity and quality of haematopoietic reconstitution161. It seems 
possible that measurement of the quantity of CD34+ mobilised with G-CSF 
administration can serve as a surrogate for effects of this cytokine on primitive cells that 
are capable of localising to ischaemic regions of the heart and regenerating myocardial 
and vascular cell lines.  Administration of exogenous G-CSF and SCF mobilizes 
pluripotent Lin⁻ c-kit⁺ cells from the bone marrow to the peripheral blood162. This 
increase in mobilisation into the circulation may create a favourable microenvironment 
for stem cell homing to the myocardium, enhance survival and induce angiogenesis163. 
Pre-treatment with G-CSF has also been shown to have a direct anti-apoptotic effect on 
cardiomyocytes164 (Table 2). G-CSF has a direct protective effect on the myocardium 
including reducing fibrosis and adverse cardiac remodelling, inhibiting apoptosis and 
inflammation and enhancing cardiac function and myocyte regeneration. There is data 
to support the safety and efficacy of exogenous G-CSF as a treatment strategy for heart 
failure165,166, and there are no reported long-term side effects following short courses of 
G-CSF in DCM. Self limiting side effects of G-CSF include bone pain, transient 
elevation in cardiac and liver enzymes165, and transient impairment of renal function166.  
Caution should therefore be exercised when G-CSF is given to patients with pre-
existing renal impairment. 
3.1.1. G-CSF therapy in AMI 
Orlic and co-workers97 were  able to demonstrate that primitive cells could be mobilised 
from the bone marrow in a mouse model of myocardial infarction using a combination of 
the cytokine SCF and G-CSF. Treatment with these cytokines for 5 days prior to 
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coronary artery ligation and for 3 days afterwards resulted in reduction in mortality, 
infarct size, magnitude of cavity dilatation and diastolic stress at 27 days post-infarct 
compared with saline-injected animals. Left ventricular ejection fraction, as measured by 
echocardiography, was greater in cytokine-treated animals compared with controls. 
Although phase 1 clinical trials after myocardial infarction showed that G-CSF treatment 
was safe and associated with possible beneficial effects on left ventricular systolic 
function167,168, a subsequent randomised placebo controlled study of subcutaneous G-
CSF after primary PCI for AMI infarction showed no additional improvements in left 
ventricular function when compared to placebo169. This was confirmed in a meta-
analysis on the effect of G-CSF in AMI which showed no overall benefit although subset 
analysis showed there may be benefit limited to patients with LV systolic dysfunction 
and if the infusion is started early170. There has also been concerns raised regarding the 
potential of G-CSF to cause in-stent restenosis (ISR) as it the increases the level of 
circulating neutrophils which may accelerate the process of neointimal proliferation171. 
One of the initial clinical trials reported an unexpectedly high rate of ISR in 10 patients 
treated with G-CSF following an AMI172. However, a more recent trial involving patients 
with large infarcts and late revascularisation did not show any increased incidence of 
ISR173. Furthermore, Jorgensen et al demonstrated by using intravascular ultrasound 
(IVUS), 5 months after stent insertion for AMI, no increased in-stent neointimal 
hyperplasia in the G-CSF treatment group compared to placebo174. It remains to be 
determined if G-CSF treatment could be an effective part of a treatment strategy 
combining several cytokines and/or local stem cell delivery. 
40 
 
 
3.1.2. G-CSF therapy in IHD 
G-CSF treatment in patients with ischaemic cardiomyopathy (ICM) and DCM given as 
four 10-day treatment periods interrupted by treatment-free intervals of equal length, 
resulted in an improvement by one New York Heart Association (NYHA) class and a 
statistically significant increase in six-minute walking distance compared to historical 
controls166. In this study, patients with ICM experienced an increase in episodes of 
dyspnoea or angina and one of the subjects had an episode of fatal ventricular 
fibrillation, although this may have been due to the presence of underlying severe 
coronary artery disease. Another study showed that administering 5μg/kg/day for 5 
days to patients with ICM and advance heart failure (EF<35% and NYHA III-IV) 
resulted in a significant improvement in LVEF165. Interestingly G-CSF significantly 
increased the plasma levels of the anti-inflammatory cytokine IL-10 without an effect 
on pro-inflammatory cytokines levels. Other studies have demonstrated that G-CSF 
inhibits pro-inflammatory cytokines like interleukin 1, tumour necrosis factor-α and 
interferon-γ164. This positive effect on the anti/pro inflammatory cytokine ratio may 
confer a benefit in patients with heart failure. In a more recent study, 10 µg/kg/day  of 
G-CSF was administered  for 5 days to severely symptomatic patients with ICM not 
amenable to revascularisation (CCS and NYHA ≥ III). This resulted in a significant 
reduction in CCS and NYHA from IV to III and III to I at 4 month follow-up175. 
These trials demonstrate that G-CSF therapy in patients with heart failure due to ICM 
is safe and feasible and maybe associated with an improvement in the clinical and 
biochemical status. 
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3.1.3. G-CSF therapy in DCM 
Endogenous G-CSF is a potent hematopoietic cytokine that affects progenitor cell 
proliferation, maturation and functional activation159,176, and enhances the mobilization 
and recruitment of stem cells from the bone marrow to the circulation160,177. 
Administration of exogenous G-CSF and stem cell factor mobilizes pluripotent Lin-c-kit+ 
cells from the bone marrow to the peripheral blood162,178. This increase in mobilization 
into the circulation may create a favorable microenvironment for stem cell homing to the 
myocardium, enhance survival and induce angiogenesis163,178. Pretreatment with G-
CSF has also been demonstrated to have a direct anti-apoptotic effect on 
cardiomyocytes. There are data to support the safety and efficacy of exogenous G-CSF 
as a treatment strategy for heart failure145,166, and there are no reported long-term side 
effects following short courses of G-CSF in DCM. Self-limiting side effects of G-CSF 
include bone pain, transient elevation in cardiac and liver enzymes, and transient 
impairment of renal function166,179 
In animal studies, stem cell and cytokine therapy in DCM led to an improvement in 
cardiac function137,180. In the non-ischemic heart failure model, significant increases in 
the survival rate and cardiac function were achieved by cell therapy and cytokine 
therapy inhibited the fibrosis and apoptosis of the cardiomyocytes137. G-CSF receptors 
are expressed on cardiomyocytes in idiopathic dilated cardiomyopathy181. In  
 
doxorubicin- induced cardiomyopathy, early administration of G-CSF enhanced the 
migration of bone marrow cells into the heart, and attenuated the cardiotoxicity of 
doxorubicin180. G-CSF has an ‘indirect effect’ on bone marrow to mobilize cells to 
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migrate into diseased heart and a ‘direct’ effect on cardiomyocytes through G-CSF 
receptors resulting in increase in homing of stem cells into the myocardium and an 
improvement in cardiac function (Figure 2). The improvement in LV function in DCM 
animal models was not translated in the small pilot study using G-CSF in heart failure 
patients165. It remains to be determined if G-CSF treatment could be an effective part of 
a treatment strategy combining several cytokines and/or local stem cell delivery.
 
Figure 2: Mechanism of action of G-CSF in DCM 
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4. CLINICAL TRIAL 
4.1.1. Rationale  
A number of preclinical trials and pilot studies have demonstrated the safety and 
efficacy of stem cell therapy in DCM (summarised below). However, there are no 
randomised control trials in this field. We therefore aimed to conduct the first 
randomised control trial to assess the role of intracoronary injection of bone marrow 
derived stem cells compared with placebo in patients with DCM pre-treated with G-CSF, 
and to evaluate the effect of G-CSF administration on cardiac function and symptoms in 
patients with idiopathic dilated cardiomyopathy. 
 
4.1.2. Summary of previous trials:   
Intramyocardial injection of mesenchymal stem cells (MSCs) in a mouse model was 
associated with enhanced LV remodelling and an improvement in survival137, as well as 
induction of angiogenesis and inhibition of myocardial fibrosis100. In a swine model of 
heart failure with normal coronary arteries, transplantation of autologous MSCs over 
expressing VEGF prevented LV decompensation, induced neovascularisation and 
improved myocardial blood flow182. Promising results from these animal studies in DCM 
led to the publication of small pilot studies creating further excitement by showing that 
stem cell transplantation led to an improvement in cardiac function, symptoms and ven-
tricular remodelling after intramyocardial and intracoronary injection (table 3). A pilot 
study of intracoronary stem cell implantation in patients with DCM showed a significant 
improvement in ejection fraction of 5.4% and an improvement in NYHA functional class 
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in the treatment group at a 6-month follow-up142. A case report of intracoronary injection 
of autologous bone marrow progenitor cells resulted in a reduction of NYHA class from 
IV to I, an improvement of ejection fraction from 20 to 45% and a significant reduction in 
plasma BNP levels at 6-month follow-up143. In the Transplantation Of Progenitor Cells 
And Recovery of Left Ventricular Function in Patients with non ischemic Dilated 
Cardiomyopathy (TOPCARE-DCM) trial, intracoronary administration of BMC was 
associated with regional and global improvement in LV ejection fraction at 3 months 
follow-up associated with an improvement in microvascular function144. More recently, a 
pilot randomized trial demonstrated that intracoronary delivery of autologous CD34+ 
cells improved LV function and exercise tolerance, and potentially improved survival145.  
Although the results of these studies are encouraging, it is difficult to draw any 
conclusive evidence regarding the efficacy of cytokine and stem cell therapy as most of 
these trials were not randomized and did not include a control group. 
4.1.3.  Study background and hypothesis 
The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy 
(REGENERATE-DCM) trial is to my knowledge the first randomized, placebo controlled 
trial worldwide to investigate the role of granulocyte-colony stimulating factor  (G-CSF) 
and autologous bone marrow derived progenitor cells to improve cardiac function in 
patients with non ischemic DCM. The main objectives of the study were: 
To conduct an appropriately powered, randomized, placebo-controlled trial to evaluate 
the role of intracoronary injection of BMSCs compared with placebo infusion in patients 
with DCM, pre-treated with G-CSF; 
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Evaluate the effect of G-CSF administration on cardiac function and symptoms in 
patients with idiopathic DCM; 
Assess whether direct coronary injection of autologous bone marrow-derived stem cells 
will confer an additional improvement in cardiac function and symptoms above that 
derived from G-CSF injection alone. 
4.1.4. Study hypothesis: 
1- Administration of G-CSF to patients with idiopathic dilated cardiomyopathy will lead to 
an increase in circulating progenitor cells as measured by peripheral CD34+ positive 
cell counts. 
2- Cardiac function and symptoms will improve in patients in whom the peripheral 
CD34+ counts increase in response to G-CSF administration. 
3- Direct coronary injection of autologous bone marrow derived stem cells will confer an 
additional improvement in cardiac function and symptoms above that derived from G-
CSF injection alone. 
 
This multicenter study was conducted at the London Chest hospital (Barts and the 
London NHS Trust, UK), The Heart hospital (University College London Hospitals 
NHS Trust, UK) and the Royal Brompton hospital (Royal Brompton and Harefield 
NHS Trust, UK). Patients were recruited from hospitals and heart failure clinics 
throughout the UK. The patient population of interest are symptomatic patients (NYHA 
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II–III) with a confirmed diagnosis of DCM, who are on optimal heart failure treatment 
and have no other treatment options. 
4.1.5. Methods and study design 
The study was powered to the primary end point of a within group change in LVEF at 3 
months as measured by advanced cardiac imaging.  The sample size was calculated to 
detect an improvement in LVEF of 3.5%, as demonstrated by a contemporary meta-
analysis of previous cell therapy Phase I/II trials183. 
Analysis was based on the intention-to-treat principle. Baseline demographic and 
clinical variables were summarised for each group of the study. Continuous variables 
are presented as means ± SD and categorical variables are presented as percentages.  
95% confidence intervals (CI) are given. P-values are two-sided with a value of < 0.05 
considered to indicate statistical significance.  Statistical analyses were performed 
using SPSS version 19 (IBM Corp. Armonk, NY, USA) and graphs produced using 
Graphpad Prism version 5.0 (GraphPad Software, San Diego, CA). 
Prior to recruitment, a full clinical history and examination was made to confirm that the 
patient met the inclusion criteria and had none of the exclusion criteria. A recent 
coronary angiogram was required on all patients confirming that there was no significant 
coronary disease to account for LV dysfunction. 
A 12 lead electrocardiogram was recorded at first assessment. Blood samples were 
taken for measurement of full blood count, renal function, creatinine kinase (CK), 
Troponin T, C-reactive protein, liver and thyroid function tests, HbA1c, glucose and total 
cholesterol. Blood samples are also taken for HIV, Hep B & C, HTLV and syphilis.  
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The study was conducted in full accordance with the principles of the Declaration of Helsinki and 
was approved by the Local Research Ethics Committee. Informed consent was obtained from all 
patients prior to inclusion in the study. A total of 60 patients were randomly assigned to one of the 
2 arms of the trial: (Figure 1) 
I) Peripheral mobilization with G-CSF or placebo injections (peripheral arm) 
II) Intracoronary delivery of bone marrow-derived stem/progenitor cells or serum 
(placebo) following G-CSF injections (intervention arm). (See diagram of study 
design) 
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Figure 3: Study design of the REGENERATE-DCM trial 
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Randomisation took place on a web based database created for the study. A baseline 
exercise test with VO2 max and a cardiac MR/CT was performed on all subjects at 
baseline. In addition, overall quality of life is assessed using EQ-5D quality of life 
questionnaire whilst quality of life related to heart disease was specifically measured 
using the Kansas City Cardiomyopathy Questionnaire. Half of the subjects in the non-
intervention arm were randomised to placebo injection and half to receive a standard G-
CSF dose of 10 μg/kg/day (263 microgram in 1ml) given subcutaneously for 5 days. All 
patients randomised to the interventional arm of the study had 100 ml of bone marrow 
aspirated following 5 days of G-CSF subcutaneous injection. The dose of G-CSF we 
used was 10 μg/kg/day (263 microgram in 1ml). This dose is similar to doses used for 
stem cell mobilisation in advanced chronic heart failure, and was shown to be sufficient 
to mobilise progenitor cells into the peripheral blood in adequate numbers166. The bone 
marrow samples are processed and analysed for cellular composition and function in a 
fully compliant Good Manufacturing Practice (GMP) laboratory. The cell suspension or 
placebo is infused using a stop-flow technique through an over-the-wire percutaneous 
balloon catheter method. The placebo solution consists of patient’s own serum. 
Bone Marrow Harvest and isolation of BMMNC 
Following written consent, bone marrow samples were obtained from patients from the 
posterior superior iliac spine using a 15-gauge bone marrow aspiration needle. A total of 
5 ml of bone marrow was aspirated into a 10 ml syringe containing 1 ml heparin sodium.  
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A total of 100 ml of bone marrow was aspirated equally into 20 × 10 ml heparin-treated 
syringes. The bone marrow aspirates was then kept at room temperature whilst awaiting 
transfer to the stem cell laboratory. The Ficoll-Paque density gradient media was used 
for cell isolation as follows: Bone marrow aspirates from the heparin-treated syringes 
were pooled into a single transfusion bag. The entire volume (100 ml) was passed 
through a blood component transfusion set with a 200µm filter. A total of 25 ml of this 
volume was then layered on 50 ml of Ficoll-Paque (density gradient: 1.077 ± 0.001 g/ml) 
and the remaining 50 ml of bone marrow layered on 25 ml of Lymphoprep. Both 
preparations were centrifuged in a Sorvall RT Legend centrifuge at 2500 rpm for 30 min 
with the brake off. The BMMNC layer from each preparation was extracted and spun 
again at 2500 rpm for 10 min with the brake off. The resulting cell pellets were re-
suspended and underwent two cycles of washing in 0.9% saline. The final cell pellets 
were re-suspended in 2 ml autologous serum. Serum was obtained from 6 × 7 ml plain 
red-top vacutainers of peripheral blood, which had been allowed to clot and centrifuged 
in a Sorvall RT Legend centrifuge at 2500 rpm for 5 min to yield autologous serum. 
Each cell suspension was passed through a 100µm filter which was rinsed through with 
0.5 ml autologous serum.  
4.1.6. Patient population 
The patient population of interest are symptomatic patients (NYHA II-III) with a 
confirmed diagnosis of dilated cardiomyopathy who are on optimal heart failure 
treatment including device therapy (biventricular pacemaker & internal 
cardio defibrillator)  , and have no other treatment options. Exclusion criteria include: 
Documented latest ejection fraction >45% on echocardiogram, the presence of 
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cardiogenic shock or acute decompensated heart failure, severe left ventricular 
dysfunction (ejection fraction <10%), congenital cardiac disease, cardiomyopathy in 
association with a neuromuscular disorder, previous cardiac surgery, serious known 
concomitant disease with a life expectancy of less than one year, the presence of atrial 
fibrillation unless paced, renal impairment (Creatinine >200mmol/L),  neoplastic disease 
without documented remission within the past 5 years (see table below).  
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Table 6: REGENERATE-DCM: Inclusion/Exclusion criteria for the trial 
Inclusion criteria Exclusion criteria 
 Symptomatic patients (NYHA II-
III) with a confirmed diagnosis 
of DCM with an ejection fraction 
<45% who are on optimal 
medical therapy for at least 6 
months with no further 
treatment options 
 
 Left ventricular ejection fraction < 10% 
 Cardiogenic shock 
 Congenital cardiac disease 
 Cardiomyopathy due to a reversible 
cause 
 Cardiomyopathy in association with a 
neuromuscular disorder (eg: 
Duchenne’s muscular dystrophy)  
 Previous cardiac surgery 
 Contra-indication to bone marrow 
aspiration 
 Known active infection 
 Chronic active inflammatory disease 
 Serious known concomitant disease 
with a life expectancy of < 1 year 
 Atrial fibrillation (unless paced ) 
 Renal impairment (Creatinine >200 
mmol/L) 
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 Neoplastic disease without documented 
remission within the past  5 years 
 
4.1.7. Safety endpoints and outcome measurements 
Follow-up assessments were performed at 3 and 12 months. All primary end point 
measurements were performed in a core laboratory by investigators who remained 
blinded to treatment assignment. Importantly, the safety end point of major adverse 
cardiac events was closely monitored by an independent safety committee. The primary 
end point is change in LV ejection fraction as measured by cardiac MR or CT at 
3 months. The secondary end points are as follows:  
 Change in Concentrations of NT-proBNP (cardiac enzyme), 
 Changes in V02 max (exercise capacity) 
 Changes in ejection fraction, ventricular dimensions as measured by cardiac 
MRI/ CT at 12 months. 
 Functional class changes according to NYHA and quality of life (QoL - EQ-5D 
& Kansas City) questionnaires, 
 Occurrence of a Major Adverse Cardiac Event (MACE) defined as cardiac 
death, myocardial infarction (CK / CK-MB over 2 times the upper limit of 
normal) & 
 Hospitalisation for Heart failure & the occurrence of major arrhythmias defined as 
symptomatic ventricular tachycardia or survived sudden death 
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4.1.8. Cardio-pulmonary exercise testing 
In chronic heart failure, cardio-pulmonary exercise testing is established as the 
mainstay of objective measurement of functional ability. One of the key parameters 
measured is peak oxygen consumption (peak VO2) and VE/VCO2 slope which have 
been shown to be important prognostic markers176,184,185. Peak VO2 represents the 
highest rate of oxygen uptake as oxygen consumption rises incrementally during 
exercise. A variety of factors may result in reduction of peak VO2 level including low 
cardiac output, reduced peripheral blood flow, impaired skeletal muscle metabolism or 
early termination of the test. Although left ventricular ejection fraction does not predict 
peak VO2, patients with low peak VO2 have a higher mortality rate. Studies have shown 
that mortality of patients with a peak VO2 of 14.5 mL/kg per minute or less was double 
that of patients whose VO2 exceeded this value177,186. Normally, peak VO2 decreases 
with age, declining 5% to 10% per decade of life. At any age, peak VO2 is 10% to 20% 
higher in men than women, in part because of a higher hemoglobin concentration, a 
larger muscle mass, and a greater stroke volume in men. As a result, the measured 
VO2max will be compared with a predicted value generated from empirically derived 
formulas based on age, sex, and height. The peak VO2 would be considered decreased 
if the measured value is less than 85% of predicted178,186. 
The major link between the circulatory and ventilatory responses to exercise is carbon 
dioxide production. Ventilatory efficiency is defined by linking ventilation relative to 
carbon dioxide production, resulting in the matching of ventilation and perfusion178,187. 
VE/VCO2 is the ventilation- carbon dioxide production ratio and the VE/VCO2 slope is 
the rate of increase in ventilation per unit increase in carbon dioxide production. This is 
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greater in patients with chronic heart failure compared to normal individuals, and higher 
than normal values are associated with poor exercise tolerance and a worse prognosis.                                  
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5. BIOMARKER SUB-STUDY 
5.1. Background 
Patients with heart failure have an increased level of circulating brain natriuretic peptide 
(BNP) and inflammatory cytokines (e.g. IL-6 and TNF-α). Over expression of these 
cytokines are associated with the progression of LV dysfunction and worsening of heart 
failure symptoms188. A number of trials have indicated that inflammation is a strong 
predictor of future death and CHF in patients with acute coronary syndrome (ACS)189-
191. In particular, a more recent study showed that increased production of IL-6, MCP-1, 
and NT-proBNP after an ACS are at greater risk for subsequent HF and death192.  
Elevation of CRP, an inflammatory marker, is a predictor of development of heart failure 
and death after a MI193,194. In the acute setting, CRP is a sensitive pro-inflammatory 
biomarker but is not specific to cardiovascular disorders. More specific pro-inflammatory 
biomarkers such as IL-6, MCP and BNP have more recently been shown to be 
independent and powerful predicators of death and heart failure in patient s with ACS192 
(see figure).  In a randomized, placebo-controlled trial of patients with ST segment 
elevation MI, daily treatment with interleukin Ra (IL-Ra), a naturally occurring Il-1 
receptor, for 14 days after angioplasty resulted in a reduction in left ventricular 
remodelling and a reduction in CRP195. Furthermore, after 18 months, stage IV heart 
failure developed in 60% of the placebo group, compared to none in the ILRa-treated 
patients. Atherosclerosis, the underlying cause of CAD and myocardial infarction, is now 
known to be heavily influenced by inflammation. The expression of inflammatory 
molecules, such as BNP, IL-6, IL-10 and TNF-α, are increasingly recognised as markers 
of underlying disease activity and are likely to be future therapeutic targets.  
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 For example, established heart failure therapies such as B-blockers196 and ACEI197 are 
associated with a significant reduction in inflammatory cytokines.  
5.2. Biomarker sub-study Hypothesis 
The hypothesis of this sub-study is: 
1- Administration of G-CSF to patients with idiopathic dilated cardiomyopathy will lead to 
a reduction in plasma BNP levels and pro-inflammatory cytokines. 
 
2- Cardiac function and symptoms will improve in patients in whom the levels of 
plasma BNP and pro-inflammatory cytokines have decreased in response to G-
CSF administration. 
3- Direct coronary injection of autologous bone marrow derived stem cells will 
confer an additional reduction in the levels of plasma BNP and pro-inflammatory 
cytokines above that derived from G-CSF injection alone. 
 
4- A reduction in plasma BNP and pro-inflammatory cytokines has a positive 
correlation with improvements in cardiac function and symptoms. 
 
5.3. Brain Natriuretic Peptide 
Brain natriuretic peptide (BNP) is produced as a pro-hormone (Pro-BNP) from the 
ventricular and atrial myocardium in response to pressure overload and ventricular 
dilatation. It was first identified in pig brains in 1988. BNP has been established as a 
valuable marker for the diagnosis, prognosis and treatment of heart failure. In the 
setting of acute heart failure, BNP measurement has been found to be superior to 
clinical judgment for providing an accurate diagnosis198. A serum level of BNP > 100 
pg/ml has a sensitivity of 90 percent and a specificity of 76 percent for the diagnosis of 
CHF, and levels of <50 pg/ml have a negative predictive value of 96%198. In patients 
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presenting with dyspnoea to the emergency department, a BNP value of 480 pg/ml had 
a sensitivity of 68%, specificity of 88%, and an accuracy of 85% for predicting a 
subsequent heart failure end point. Patients with BNP levels > 480 pg/ml had a 51% 6-
month cumulative probability of a heart failure event, whereas those with BNP levels < 
230 pg/ml had an excellent prognosis with only a 2.5% incidence of heart failure end 
points199. 
BNP has diuretic, natriuretic and anti-hypertensive effects by inhibiting the renin-
angiotensin-aldosterone system, and exhibit a paracrine effect that inhibits fibrosis and 
hypertrophy and enhance diastolic function199. Studies have demonstrated that high 
BNP levels have a high correlation with the degree of left ventricular dysfunction, 
symptom severity and mortality in patients with congestive heart failure (CHF)200-203. 
BNP has also been shown to independently predict the morbidity and mortality in 
asymptomatic left ventricular systolic dysfunction204 and in mild to moderate CHF205. In 
a prospective study, evaluating over 3000 patients without heart failure from the 
Framingham Heart Study to determine the usefulness of BNP in predicting the risks for 
all-cause mortality, CHF, acute coronary syndrome, atrial fibrillation, and stroke, 
researchers found that high levels of BNP were associated with a 27% increase in risk 
of all-cause mortality, a 28% increase in risk for a first cardiovascular event, and a 77% 
increase in the risk of CHF203. Medications used to treat CHF decrease serum levels of 
BNP. Increased or persistent elevation of BNP despite treatment indicates progression 
of disease or lack of response to therapy, and is an indication for the need to intensify 
the treatment.  In the Val-HeFT trial, patients with the greatest decline in BNP from 
baseline after treatment had the lowest mortality rates, whereas patients with greatest 
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increase in BNP had the highest11. Several trials have compared BNP guided treatment 
and clinically guided treatment on clinical outcomes. In these studies there were 
significantly fewer events – death or heart failure hospitalization – in the BNP group 
than in the clinical group206,207. BNP guided treatment was associated with a 25% 
reduction in the median level of total treatment cost and hospital stay208. Furthermore, 
BNP has been shown to be a strong independent predictor of sudden death in patients 
with CHF209. The study by Gardner et al demonstrated that in patients with advanced 
heart failure, BNP levels above the median value was the only independent predictor of 
mortality and the combined endpoint of mortality or urgent transplantation210. Therefore 
measuring BNP levels would aid in deciding which of the advanced heart failure patients 
may benefit from the scarce resources of a cardiac transplant210. BNP provides 
important prognostic information in CHF that is independent of hemodynamic 
parameters such as pulmonary –capillary wedge pressure and LVEF211. Therefore, 
these findings suggest that plasma BNP concentration is a sensitive biomarker of left 
ventricular impairment or dysfunction.  
This section summarises the hypothesis of the biomarker sub-study and the 
methodology I used to measure the pro-inflammatory cytokines using the Randox 
Biochip technology. 
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5.4. Randox Biochip technology 
 
The Evidence Investigator™ Biochip Array technology is used to perform simultaneous 
quantitative detection of multiple analytes from a single patient sample.  
The core technology is the Randox Biochip, a solid-state device containing an array of 
discrete test regions of immobilised antibodies specific to different cytokines and growth 
factors. A sandwich chemiluminescent immunoassay is employed for the cytokine array. 
Increased levels of cytokine in a specimen will lead to increased binding of antibody 
labelled with horseradish peroxidase (HRP) and thus an increase in the 
chemiluminescence signal emitted. The light signal generated from each of the test 
regions on the biochip is detected using digital imaging technology and compared to 
that from a stored calibration curve. The concentration of analyte present in the sample 
is calculated from the calibration curve. Several different immunoassay based multi-
analyte arrays have been developed for use on Evidence Investigator™. The Evidence 
Investigator™ Cytokine Array will quantitatively test for IL-1α, IL-1, IL-2, IL-4, IL-6, IL-
8, IL-10, VEGF, IFN, EGF, MCP-1 and TNF simultaneously.  
I used patients’ serum that has been stored frozen in small aliquots at -80 C for the 
Evidence Investigator™ Cytokine & Growth Factors Array. 
Sample preparation was carried out in accordance with the collection tube 
manufacturer’s recommendations (collection devices were durable, leak-proof and 
constructed of non-absorbing plastics).  Samples were diluted using working strength 
wash buffer. 
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Test procedures:  
 
 CALIBRATION 
A nine-point calibration was performed using the Randox Evidence Investigator™ 
Cytokine & Growth Factors calibrators, which cover the measuring range of all 
assays.  A total of 6 biochip carriers were assayed simultaneously, and a new 
calibration curve was constructed for each assay series. 
 
 Quality control 
 Randox Cytokine Multianalyte Controls, level I, II, III were used for quality control in the     
monitoring of accuracy and precision. The controls should be assayed at intervals defined 
by the user. Control results should fall within acceptable limits, otherwise corrective action 
should be taken as established by laboratory guidelines. 
 
 Materials 
All materials were equilibrated to room temperature prior to use.  The required number 
of biochip carriers was removed from their packaging.  The handling tray supplied with 
the Investigator thermo shaker unit was placed onto the working surface.  Each carrier 
was inserted into the handling tray, ensuring they are flat and secure by clicking into 
position.  All sample and reagent additions, washing and incubations were performed 
using the handling tray and carriers were removed from this for the final signal addition 
and imaging stage of the procedure. The thermo shaker was equilibrated to 37C for 30 
minutes prior to use. 
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5.4.1. Interleukin 1α (IL-1α):  
The Evidence Investigator™ Interleukin-1 alpha (IL-1) test has been designed for the 
quantitative measurement of IL-1 in human serum and plasma samples. Interleukin-1 
(IL-1) is a regulatory and inflammatory cytokine, which exists in two forms, IL-1 and IL-
1, which share 25% homology at amino acid level. IL-1 is produced as a biologically 
active 31-kDa precursor, which undergoes proteolytic cleavage yielding a 17-kDa 
protein of 159 amino acids. There are 2 cell surface binding proteins for IL-1 expressed 
on various cells, IL-1R1 and IL-1R2, and one non-binding receptor accessory protein IL-
1-Racp. IL-1 and IL-1 bind to both receptor types but IL-1 binds better to IL-1R1 
than IL-1R2.  IL-1RI is an 80 kDa glycoprotein, which has been isolated from T-cells, 
fibroblasts, keratinocytes, endothelial cells, synovial lining cells, chondrocytes and 
hepatocytes and IL-1R2 has been found in B-cells, neutrophils and bone marrow 
cells212.  In healthy people cells of the central nervous system, some epithelial cells and 
skin keratinocytes produce IL-1. It is also produced by macrophage and many other 
cell types in response to stimuli by inflammatory agents, infections or microbial 
endotoxins212. IL-1 has been shown to induce synthesis of endothelial cell-surface 
factors and activate endothelial cells.  In the liver, it initiates an increase in hepatic 
protein synthesis and decreased albumin production. IL-1 also induces collagenase 
production and has been found to be chemotactic and stimulatory for neutrophils. IL-1 
also affects the endocrine system and is mitogenic for B-lymphocytes.  It also plays an 
important role in immune functions by activating macrophages, natural killer cells and T-
cells and by inducing B-cell proliferation and maturation and LAK production. IL-1 is not 
commonly found circulating except during severe disease where the cytokine is 
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released from dying cells. Colonic tissue levels of IL-1 correlate to severity of 
inflammatory bowel disease. IL-1 production is increased in sepsis, rheumatoid arthritis, 
leukaemia, diabetes and atherosclerosis212,213. The assay range for IL-1 is 0-500 
pg/ml, with <1% cross-reactivity with other cytokines.  
5.3.4 Interleukin 1ß (IL-1ß):  
IL-1 is synthesised as a biologically inactive precursor of 269 amino acids with a 
molecular mass of 31 kDa, which undergoes proteolytic cleavage by IL1 converting 
enzyme, which yields a 17kDa protein of 153 amino acids.  IL-1 plays a central role in 
acute and chronic inflammation, both locally and systemically. It is produced by 
monocytes, macrophages, astrocytes, oligodendroglia, adrenal cortical cells, natural 
killer cells, endothelial cells, keratinocytes, platelets, neurons, neutrophils, osteoblasts, 
Schwann cells, trophoblasts and fibroblasts and affects nearly every cell type. IL-1 
activates macrophages, induces fibroblast proliferation, and induces expression of 
matrix metalloproteinases, leading to extracellular matrix degradation, monocyte 
migration and degradation of IL-1, which acts as a negative feedback mechanism.  IL-
1 has a cytotoxic effect on normal cells and the IL-1 form is growth-inhibitory and 
cytocidal for certain melanoma cells.   IL-1 has been shown to inhibit insulin release 
and therefore may play a role in the development of autoimmune insulin-dependent 
diabetes mellitus.  It is also involved in bone remodelling by stimulating bone resorption 
and inhibiting bone collagen synthesis. The production of IL-1 is increased in sepsis, 
rheumatoid arthritis, leukaemia, diabetes and atherosclerosis214.The Evidence 
Investigator™ IL-1 assay that we used in our study is a sandwich chemiluminescent 
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immunoassay that detects IL-1 in human serum and plasma. The biochip substrate 
contains immobilised monoclonal antibody to IL-1. The assay range for IL-1 is 0-250 
pg/ml, with <1% cross-reactivity with other cytokines.  
5.4.2. Interleukin-2 (IL-2):  
IL-2 is a glycoprotein with a molecular mass of 15-18 kDa that has varying degrees of 
glycosylation accounting for the observed molecular weight range.  IL-2 is synthesised 
as a precursor protein of 153 amino acids from which 20 amino acids are cleaved to 
produce the active form215.  It has a single disulphide bond that is essential for biological 
activity.  The IL-2 receptor consists of three distinct membrane associated units that 
bind IL-2 with high affinity: a 55kDa  chain, a 70-75 kDa α chain and a 64 kDa  chain. 
Soluble IL-2R and IL-2Rα have been found in serum.  IL-2 is a lymphokine that is 
synthesised and secreted primarily by T-cells following their activation by mitogens or 
antigen-activated T-lymphocytes.  Transformed T-cells and B-cells, leukaemia cells, 
lymphokine activated killer cells and natural killer cells also secrete IL-2 in small 
amounts. Due to its effects on T-cells and B-cells IL-2 is a central regulator of immune 
responses216. It stimulates proliferation of T-cells, activated B-cells, natural killer cells, 
monocytes, thymocytes and lymphokine activated killer cells. It causes differentiation of 
activated B-cells, monocytes and oligodendrocytes. It also stimulates the cytolytic 
activity and cytokine production by activated B-cells, monocytes, natural killer cells and 
thymocytes. IL-2 supports the induction and secretion of immunoglobulins217.  It plays a 
role in anti-inflammatory reactions and in tumour surveillance. IL-2 stimulates the 
synthesis of IFN and IL-4 by T-cells as well as inducing secretion of IL-1 and TNF-. 
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IL-2 is also a possible neuromodulator and growth regulator of glial cells, and has been 
found to damage the blood brain barrier. IL-2 and IL-2R are elevated in Hodgkins 
disease, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, AIDS, severe burn 
trauma and allograft rejection. Antibodies against IL-2 and IL-2R may suppress immune 
responses and prevent rejection. IL-2 has also shown some promise as an anti-cancer 
drug due to the ability to activate tumour-attacking LAK and TIL cell but problems have 
arisen with toxicity218. The Evidence Investigator™ IL-2 assay that we used in our study 
is a sandwich chemiluminescent immunoassay that detects IL-2 in human serum and 
plasma. The assay range for IL-2 is 0-3000 pg/ml, with <1% cross-reactivity with other 
cytokines. 
5.4.3. Interleukin 4 (IL-4):  
IL-4 is a glycoprotein synthesised as a precursor protein of 153 amino acids.  The first 
24 amino acid residue signal peptide is cleaved to produce a 129 amino acid 15-19 kDa 
protein. IL-4 has two glycosylation sites at two arginine residues and contains six 
cysteine residues involved in disulphide bond formation, which are essential for 
biological activity. It exerts biological activity through a high affinity receptor expressed 
by cells of haemopoietic lineage.  The IL-4 receptor is produced as a 825 amino acid 
precursor glycoprotein that is cleaved to produce a mature protein of 800 amino acids 
which in turn has a 24 amino acid transmembrane domain, a 569 amino acid 
intracellular domain and a 207 amino acid extracellular domain. IL-4 is produced by 
activated T-cells, mast cells, eosinophils and peripheral basophils and its synthesis is 
induced by IL-2 and inhibited by TGFα. IL-4 induces T cell differentiation and inhibits T 
cell cytokine production. It also enhances the proliferation and differentiation of 
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activated B-cells. A further role of IL-4 is in the induction of IgE synthesis by B cells and 
the expression of class  MHC antigens.  IL-4 has also been shown to inhibit activation 
and proliferation of natural killer cells induced by IL-2 and inhibits the IL-2 dependant 
generation of LAK cells. IL-4 also inhibits the synthesis of IL-1, IL-6, IL-8, IL-10, IL-12 
and TNF in macrophages219 and promotes proliferation of mast cells and enhances 
respiratory burst and phagocytic properties of neutrophils220. IL-4 is a chemoattractant 
for fibroblasts and induces the production of extracellular matrix proteins and also 
induces proliferation of capillary endothelial cells221,222. IL-4 levels are elevated in 
disorders such as asthma and Hodgkin’s lymphoma, and may also play an important 
role in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis, and 
autoimmune disorders223.  
The assay range for IL-4 in the The Evidence Investigator™ that we used in our study is 
0-900 pg/ml, with <1% cross-reactivity with other cytokines. 
5.4.4. Interleukin-6 (IL-6):  
Interleukin (IL-6) is a pleiotropic cytokine with a broad range of humoral and cellular 
immune effects relating to inflammation, host defence, and tissue injury224. IL-6 is a 
central mediator of the acute-phase response and a primary determinant of hepatic 
production of C-reactive protein225. IL-6 is synthesised as a precursor protein of 212 
amino acids.  The N-terminal 28 amino acid residue signal peptide is cleaved to 
produce a 21kDa protein.  It has two potential N-glycosylation sites that have no effect 
on bioactivity.  Different post-translational alterations such as glycosylation and 
phosphorylation give various forms of IL-6 with molecular masses of 21.5-28 kDa.  The 
IL-6 receptor is a strongly glycosylated 80 kDa protein of 449 amino acids. Two different 
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forms of the receptor have been described that bind IL-6 with differing affinities, a 
soluble form of the IL-6 receptor has also been described. The IL-6 receptor is 
expressed on T cells, mitogen activated B cells, peripheral monocytes and some 
macrophage and B cell derived tumour cell types. IL-6 influences antigen-specific 
immune responses and inflammatory reactions. It is mainly produced by stimulated 
monocytes, fibroblasts and endothelial cells, but also by macrophages, T-cells, B-
lymphocytes, hepatocytes, granulocytes, smooth muscle cells, eosinophils, 
chondrocytes, osteoblasts, mast cells, glial cells and keratinocytes after stimulation226. 
IL-6 stimulates differentiation and antibody secretion of B-cells and also initiates IL-2 
production and IL-2 receptor expression.  It also activates T cells and in the presence of 
IL-2 induces differentiation. Production of acute phase proteins by hepatocytes is also 
stimulated by IL-6 and colony-stimulating activity on hematopoietic stem cells227.  
Additional bioactivities include induction of neuronal cell differentiation, induction of the 
maturation of megakaryocytes and inhibition of the growth and induction of terminal 
differentiation of M1 myeloid leukaemia cells. Measurement of IL-6 serum levels may be 
useful in monitoring the activity of myelomas and to calculate tumour cell masses. 
Excessive over-production of IL-6 has been observed in rheumatoid arthritis, multiple 
myeloma, Lennert syndrome, Kawasaki disease, Castlemans disease, cardiac 
myxomas and liver cirrhosis228.  Baseline levels of the inflammatory cytokine IL-6 are 
significantly elevated among apparently healthy men at risk for future myocardial 
infarction229, suggesting a role for cytokine-mediated inflammation in the early stages of 
atherosclerosis.. The assay range for IL-6 in the Evidence Investigator™ that we used in 
our study is 0-900 pg/ml, with <1% cross-reactivity with other cytokines 
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5.4.5. Interleukin-8 (IL-8):  
IL-8 is a member of a structurally similar family of cytokines called chemokines, which 
demonstrate chemotactic activity for neutrophils. IL-8 is a non-glycosylated protein of 8 
kDa protein and consists of 99 amino acids with a 22 residue signal peptide that is 
cleaved to generate a 77 amino acid.  Proteases yield N-terminal variants.  It can form 
non-covalent dimers, but they are not necessary for biological activity. Two classes of 
IL-8 receptors have been identified; CXCR-1 and CXCR-2, which are 7-transmembrane, 
G-protein-coupled receptors. One has high affinity for IL-8 and other chemokines and 
one has high affinity for IL-8 and low affinity for other chemokines230. IL-8 is produced in 
response to pro-inflammatory stimuli.  It is produced by monocytes, macrophages, 
fibroblasts, endothelial cells, keratinocytes, melanocytes, hepatocytes, chondrocytes, T-
cells, neutrophils, and astrocytes231,232. Il-8 activates neutrophil granulocytes and 
antagonises IgE production by B-cells.  It possesses anti-inflammatory activities and 
acts as a chemotactic for all known types of migratory immune cells.  It enhances 
metabolism of reactive oxygen species, increases chemotaxis and enhances 
expression of adhesion molecules. The assay range for IL-8 in the The Evidence 
Investigator™ that we used in our study is 0-3000 pg/ml, with <1% cross-reactivity with 
other cytokines. 
 
5.4.6. Interleukin 10 (IL-10): 
Interleukin-10 (IL-10) is a homodimeric protein with a molecular weight of 18 kDa. It is 
produced as a 178 amino acid residue precursor, which is cleaved to give a mature 
protein of 160 amino acids. It also has two intrachain disulphide bonds, which are 
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required for activity233. Receptors for IL-10 are all transmembrane glycoproteins about 
110 kDa in size. The IL-10 receptor binds to its ligand with high affinity most 
haemopoietic cells express them at low levels. IL-10 primarily acts as an anti -
inflammatory agent, inhibiting cytokine production by T cells and natural killer cells 
caused by activation of monocytes/macrophages234.  IL-10 strongly inhibits the 
production of IL-1α, IL-6, IL-8, IL-10, IL-12, GM-CSF, G-CSF, M-CSF, TNF-α, MIP-1α  
by activated monocytes/macrophages. It also inhibits the ability of 
monocytes/macrophages to modulate turnover of extracellular matrix235. It initiates 
growth and differentiation of B cells and induces histamine release by mast cells. IL-10 
also expresses an anti-inflammatory response on neutrophils and an 
immunosuppressive effect on dendritic cells236,237. Serum levels of IL-10 are decreased 
in HF and correlate negatively with severity238. IL-10 suppresses the synthesis of TNF-α 
and is thought to have a cardioprotective effect in CHF patients239. In patients with DCM 
baseline IL-10 and TNF α are elevated at baseline. Certain tumour cell lines including 
melanomas and a variety of carcinomas produce IL-10 and it is also produced during 
septicaemia and septic shock. IL-10 is involved in development of inflammatory bowel 
disease. Expression of IL-10 is detected in patients with multiple sclerosis and it has 
been suggested that it could potentially be a useful therapeutic agent for this disease. 
IL-10 also contributes to immunosuppression seen in many infectious diseases such as 
Leprosy, Malaria and HIV, which show increased IL-10 production. IL-10 alone and 
synergistically with IL-4 has been seen to reduce various symptoms observed with 
acute and chronic arthritis and daily administration of IL-10 inhibits spontaneous onset 
of insulin dependent diabetes mellitus in mice. The assay range for IL-8 in the Evidence 
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Investigator™ that we used in our study is 0-1000 pg/ml, with <1% cross-reactivity with 
other cytokines. 
5.4.7. Vascular Endothelial Growth Factor (VEGF): 
Vascular endothelial growth factor (VEGF) is secreted as a glycosylated homodimeric 
protein of 46 kDa that is made up of two 24-kDa subunits linked by disulphide bonds. 
Various molecular variants of VEGF have been identified depending on splicing of the 
mRNA: 121, 145, 165, 189 and 206 amino acids240. There are three receptors in the 
VEGF family; VEGFR1, expressed on endothelial cells, trophoblasts and macrophages 
mediates motility and vascular permeability. VEGFR2, expressed on endothelial cells, 
haemopoietic stem cells, megakaryocytes and retinal cells is essentially involved in 
proliferation. VEGFR3 is expressed specifically on lymphatic endothelium and is 
important for lymphatic proliferation. VEGF is expressed by vascularised tissue such as 
pituitary, brain, lungs, kidneys, heart and adrenal glands, although it is assumed that all 
tissues have the potential to produce the growth factor241. VEGF is a specific mitogen 
and survival factor for endothelial cells and a key promoter of angiogenesis240,242. It also 
causes vasodilation, stimulates cell migration and inhibits apoptosis243. Synthesis of 
VEGF is stimulated when cells become deficient in oxygen or glucose or under 
inflammatory conditions240.  
An increase in VEGF production has been observed in patients with preeclampsia, 
ischemic heart disease, sickle cell anaemia, psoriasis, diabetes, rheumatoid arthritis, 
POEMS syndrome and Kawasaki disease244,245. Increased serum concentrations of 
VEGF have been observed in various types of cancer. Drug development to block 
angiogenesis by interfering with VEGF function has been successful in many tumour 
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treatments. VEGF has also been used successfully in therapeutic angiogenesis in 
patients with end-stage coronary artery disease246.  
The assay range for VEGF in the Evidence Investigator™ that we used in our study is 
0-3000 pg/ml, with <1% cross-reactivity with other cytokines. 
5.4.8. Interferon- (IFN-): 
Biologically active interferon gamma (IFN) is a 20 or 25 kDa glycoprotein depending on 
its glycosylation state. This lymphokine is synthesised as a 166 amino acid sequence 
but is cleaved to give a 143 amino acid residue. It binds to a single chain 90 kDa 
glycoprotein receptor that has a high degree of specificity and is expressed on all types 
of human cells. Binding of IFN to its receptor induces expression of various proteins 
specific to IFN stimulation. IFN is produced by mitogen activated T lymphocytes and 
natural killer cells and its main role is its involvement in the regulation of immunological 
functions essential to host defense mechanisms. It has anti viral and anti-parasitic 
properties. It modulates growth and differentiation of T lymphocytes and influences cell-
mediated mechanisms of cytotoxity. It increases macrophage-mediated killing of extra-
cellular parasites and inhibits viral replication. IL2, bFGF and EGF induce IFN 
synthesis in T lymphocytes. Knock out studies have shown that IFN is not essential for 
the development of the immune response but is essential for resistance to viral 
infections247. IFN decreases clinical symptoms in severe atopic dermatitis. It also 
decreases joint pain and is effective in the treatment of chronic polyarthritis. Treatment 
of malignancies by IFN has been disappointing but combination treatment with other 
interferons has been more successful. IFN may also be useful in the treatment of 
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infections in immunosuppressed patients. Decreased levels of IFN are observed in 
acute and asymptomatic asthma and are associated with severe airway obstructions. 
Cells derived from the skin and peripheral blood supply of cutaneous T cell lymphoma 
patients have depressed levels of IFN. Studies have also observed an age related 
increase in IFN production248. The assay range for IFN in the The Evidence 
Investigator™ that we used in our study is 0-1500 pg/ml, with <1% cross-reactivity with 
other cytokines. 
5.4.9. Epidermal Growth Factor (EGF): 
Human EGF is produced as a long precursor protein of 1207 amino acids, which is 
released by protoelytic cleavage to give a globular protein of 6.4 kDa consisting of 53 
amino acids. EGF contains three intramolecular disulfide bonds, which are essential for 
its biological activity. EGF is produced by various organs including the brain, kidney, 
salivary gland and stomach, and is found in nearly all bodily fluids at low levels and at 
higher levels in saliva, milk, semen and urine.   
EGF production is stimulated by progesterone and inhibited by oestrogen and is stored 
in platelets and released on degranulation. It is mitogenic and chemotactic for epidermal 
and epithelial cells and also mitogenic for basal cells of olfactory epithelium and for 
endothelial cells and therefore plays an important role in angiogenesis249. EGF controls 
and stimulates proliferation of epidermal and epithelial cells such as fibroblasts, kidney 
epithelial cells, human glial cells, ovary granulosa cells and thyroid cells. It has been 
shown to act as a differentiation factor and increases turnover and synthesis of extra 
cellular matrix such as fibronectin, collagens, laminin and glycosaminoglycans. It may 
also influence the activity of GABA-ergic and dopaminergic neurons. EGF has various 
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therapeutic applications such as the healing of burns, venous and diabetic ulcers, skin 
graft donor sites, corneal wounds, tympanic membrane perforations, gastric and 
duodenal ulcers and increasing sensitivity of malignancies to cytotoxic drugs250. EGF 
has been shown to be elevated in patients with brain tumours and to induce 
differentiation in tumour cell lines. Also many epithelial cancers over-express the EGF 
receptor. Tumour aggressiveness is also associated with increased expression of EGF 
receptors. This expression is also high in invasive and disseminated tumours therefore 
many strategies to block the EGF receptor have been studied to inhibit tumour 
proliferation. It has also been proposed that EGF plays an important role in male 
infertility, as there is a correlation between the level of circulating EGF, and the number 
of spermatids in the testis. 
The assay range for EGF in the Evidence Investigator™ that we used in our study is 0-
900 pg/ml, with <1% cross-reactivity with other cytokines. 
 
5.4.10. Tumor Necrosis Factor –α (TNF-α): 
Tumour necrosis factor alpha (TNF-α) is a 157 amino acid 26-kDa transmembrane 
protein which is secreted as a soluble mature 233 amino acid homotrimer of 17 kDa by 
proteolytic cleavage. Both forms of TNF-α are biologically active. There are two distinct 
structurally homologous TNF receptors, which bind to TNF-α with high affinity; TNFR1 
and TNFR2. At least one receptor is expressed on nearly all cell types and soluble 
forms have been found in serum and urine. TNF-α has a role in host resistance to 
infection as a mediator of immune and inflammatory responses. Various immune cells 
75 
 
 
such as macrophages, monocytes, neutrophils, T cells and natural killer cells, following 
stimulation by lipopolysaccharide, secrete TNF- α251.  Synthesis of TNF- α is induced by 
interferons, IL-2, GM-CSF, bradykinin, immune complexes and inhibitors of 
cyclooxygenase. TNF- α production is inhibited by IL-6, TGFβ, VitD3, prostaglandin E2, 
dexamethasone and cyclosporin A. Increased production of TNF- α leads to cachexia, 
septic shock following infection by gram-negative bacteria, autoimmune disorder and 
meningococcal septicaemia252. Increased levels of TNF- α are also seen in multiple 
sclerosis, rheumatoid arthritis, brain injury, meningococcal meningitis, HIV, and 
Alzheimer’s disease253. Patients with advanced heart failure also exhibit high levels of 
TNF-α254. TNF- α is involved in the growth of malignant tumours and has been 
investigated as an antitumor drug but its use has been limited due to its systemic toxic 
side effects. Anti TNF- α has been shown to decrease inflammation in ulcerative colitis 
and is also useful in the treatment of sepsis and rheumatoid arthritis252. TNF-α is 
derived from macrophages, endothelial and smooth muscle cells. TNF- α levels are 
significantly elevated in advanced heart failure255and post MI256. Furthermore persistent 
elevation of TNF– α for > 3 months post MI is associated with up to a 3 fold increase in 
recurrent MI or coronary death257. The assay range for TNF- α in the Evidence 
Investigator™ that we used in our study is 0-1500 pg/ml, with <1% cross-reactivity with 
other cytokines. 
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6.  RESULTS 
6.1. Baseline characteristics 
A total of 60 patients were recruited for the trial. The patient baseline characteristics 
were well matched between the 4 groups (tables below). There were no significant 
differences with regards to age, sex, hypertension, ICD/pacemaker device therapy or 
treatment with disease modifying agents such as ACEi/ARB, B-blockers, diuretics, 
Aldosterone antagonists and Digoxin. All patients were on maximum tolerated medical 
therapy; Over 98% of patients were on ACEi or ARB and 88% were on B-blockers.  The 
baseline characteristics of this cohort of patients with idiopathic dilated cardiomyopathy 
are in keeping with previously published trials145,186. Of note, the prevalence of 
hypertension in our cohort was < 10% all of which were well controlled with medication.  
The baseline New York Heart Association (NYHA) classification for heart failure 
symptoms and Canadian Cardiovascular Society (CCS) classification for angina were 
similar between the groups. 
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Peripheral 
G-CSF 
Peripheral 
Placebo p-value 
IC Stem 
Cells IC Serum p-value ANOVA 
 
n = 15 n = 15 
 
n = 15 n = 15 
  Age - years 
(mean;SEM) 
52.87 ± 
3.07 
56.07 ± 
2.55 0.4298 
51.67 ± 
3.12 
54.87 ± 
3.70 0.52 0.76 
BMI - kg/m2 
(mean;SEM) 
29.19 ± 
1.39 
29.71 ± 
1.25 0.7845 
27.23 ± 
1.12 
28.26 ± 
1.8 0.636 0.6214 
Male gender - % 66.6 86.6 0.2084 66.6 60 0.7165 0.4307 
Hypertension - % 6.6 13.3 0.5589 13.3 6.6 0.5589 0.8728 
Hyperlipidemia - % 13.3 19.9 0.6383 0 6.6 0.3259 0.3081 
Diabetes - % 6.6 13.3 0.5589 13.3 6.6 0.5589 0.8728 
Active smoker - % 6.6 13.3 0.5589 13.3 13.3 >0.9999 0.9279 
Family History of CAD 
- % 6.6 13.3 0.5589 13.3 13.3 >0.9999 0.36 
Diagnosis to therapy  
duration - years 
(mean;SEM) 7.3 ± 1.95 5.4 ± 0.91 0.3677 
4.9 ± 
0.96 
8.00 ± 
1.61 0.10 0.31 
SEM; standard error of the mean 
Table 7: Baseline characteristics of the REGENERATE-DCM trial  
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Peripheral 
G-CSF 
Peripheral 
Placebo p-value 
IC Stem 
Cells IC Serum p-value ANOVA 
 
n = 15 n = 15 
 
n = 15 n = 15 
  Medical Therapy 
       Statins  46.6 53.3 0.7263 26.6 46.6 0.2712 0.6213 
ACEi 39.9 59.9 0.2893 73.3 73.3 >0.9999 0.2008 
ARB  59.9 33.3 0.1534 26.6 26.6 >0.9999 0.1876 
ACEi/ARB  100 93.3 0.3259 100 100 >0.9999 0.3997 
Aspirin   26.6 39.9 0.4560 26.6 33.3 0.7025 0.8486 
B-Blockers  79.9 100 0.0719 86.6 86.6 >0.9999 0.3963 
Diuretics  59.9 59.9 >0.9999 73.3 53.3 0.2712 0.7349 
Aldosterone 
Antagonists 53.3 79.9 0.1299 66.6 79.9 0.4265 0.3556 
Digoxin  33.3 13.3 0.2084 39.9 26.6 0.456 0.4282 
        Device Therapy 
       ICD  33.3 19.9 0.4265 26.6 26.6 >0.9999 0.8859 
Biventricular 
Pacemaker  0 6.60 0.3259 13.3 13.3 >0.9999 0.5113 
CRT-D  26.6 39.9 0.456 46.6 19.9 0.1299 0.4077 
Overall device 
therapy  26.6 46.6 0.2712 59.9 33.3 0.1534 0.2676 
ACEi; Angiotensin converting enzyme inhibitors, ARB; Angiotensin receptor blockers, ICD; implantable 
cardiac defibrillators, CRT-D; cardiac resynchronisation therapy - defibrillator 
Table 8: Baseline characteristics of the REGENERATE-DCM trial 
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Peripheral G-
CSF; Mean 
(SEM) 
Peripheral 
Placebo; Mean 
(SEM) 
IC Stem Cells; 
Mean (SEM) 
IC Serum; Mean 
(SEM) p-value 
Hb (g/dL) 13.78 (0.2566) 13.99 (0.2396) 13.60 (0.2649) 13.05 (0.2702) 0.077 
Platelets 
(x10⌃ 9/L) 236.8 (13.46) 223.8 (13.20) 226.9 (14.61) 239.7 (14.69) 0.8276 
WCC (x10⌃ 9/L) 7.020 (0.5264) 7.253 (0.6728) 7.447 (0.5242) 6.760 (0.5129) 0.8412 
      Urea (mmol/L) 7.447 (0.5714) 7.413 (0.7157) 8.247 (1.018) 7.193 (0.6636) 0.7762 
Creatinine 
(umol/L) 96.60 (5.107) 99.80 (6.472) 99.87 (6.945) 92.40 (7.421) 0.8323 
eGFR (mL/min) 70.27 (4.217) 71.73 (5.745) 71.67 (6.629) 75.80 (6.903) 0.9228 
CRP 6.800 (1.212) 6.867 (0.8776) 6.600 (1.341) 6.867 (0.7149) 0.9979 
CK 121.3 (13.60) 181.9 (40.90) 162.6 (29.96) 140.1 (17.38) 0.4405 
Trop 0.0215 (0.0078) 0.0153 (0.0031) 0.0145 (0.0028) 0.0137 (0.0038) 0.6491 
      Bilirubin 
(umol/L) 11.27 (2.126) 15.53 (4.031) 10.67 (1.190) 11.53 (1.404) 0.4908 
ALT (IU/L) 25.33 (1.443) 31.13 (4.052) 25.47 (2.160) 29.33 (4.042) 0.4759 
ALP (IU/L) 60.13 (5.710) 74.73 (6.320) 61.87 (3.690) 75.33 (9.765) 0.4934 
GGT (IU/L) 37.93 (5.319) 54.20 (11.33) 52.00 (10.68) 55.00 (13.51) 0.6403 
      Cholesterol 
(mmol/L) 5.113 (0.2916) 5.460 (0.5119) 4.887 (0.2646) 5.133 (0.2830) 0.7197 
Glucose 
(mmol/L) 7.264 (1.819) 6.280 (0.7742) 5.427 (0.2773) 5.460 (0.2476) 0.5075 
T4 17.13 (0.6994) 16.70 (1.143) 17.42 (0.8865) 18.45 (1.483) 0.7334 
TSH (IU/L) 3.275 (1.258) 5.123 (2.525) 1.953 (0.3042) 1.825 (0.2237) 0.3619 
      BNP 1640 (508.1) 1304 (318.6) 964.7 (240.0) 1474 (566.7) 0.7054 
      HbA1c 6.640 (0.6436) 6.387 (0.3733) 5.967 (0.1609) 6.113 (0.1633) 0.6260 
 
 
Table 9: REGENERATE-DCM trial: Baseline bloods  
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NYHA  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value ANOVA 
II -% 73.3 60.0 0.7408 46.7 66.7 0.2425 0.3586 
III - % 26.7 40.0  46.7 33.3   
IV - % 0 0  6.7 0   
        
        
CCS Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value ANOVA 
0 - % 93.3 66.7 0.2615 60.0 80.0 0.2919 0.4192 
I - % 6.7 13.3  6.7 6.7   
II -% 0 13.3  20.0 0.0   
III - % 0 6.7  13.3 6.7   
NYHA; New York Heart Association, CCS; Canadian Cardiovascular Society, IC; Intracoronary 
Table 10: Baseline characteristics of the REGENERATE-DCM trial 
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6.2. Primary Endpoint: Change in Ejection Fraction  
The baseline ejection fraction (EF) was similar between groups. The mean baseline EF 
in the peripheral placebo group was 28.9% compared to 36% in the peripheral G-CSF 
group (P = 0.09). The mean baseline EF in the intracoronary serum group was 41.7% 
compared to 32.9% in the intracoronary stem cell group (P = 0.14). 
At 3 months there was a significant improvement in mean EF in the intracoronary stem 
cell group from 32.9% to 38.4% (P = 0.0138). This represents a within group (Paired t-
test) change of 5.4% in EF. There was no corresponding significant improvement in EF 
in the remaining 3 groups. In the intracoronary serum group, EF reduced from 41.7% to 
40.6% (within group reduction of 1.1%) (P = 0.46). In the peripheral G-CSF group the 
EF improved from 36% to 36.6% (within group improvement of 0.6%), and in the 
peripheral placebo group the EF reduced from 28.9% to 28.68% (within group reduction 
of 0.22%).  
6.3. LV mass, LV dimensions and stroke volume 
We found no significant improvement in LV mass, end-systolic volumes, end-diastolic 
volumes or stroke volume in any of the 4 groups (tables 14,15,16,17). Ejection fraction 
is influenced by a number of confounding variables including afterload, preload, 
electrical activation pattern and neurohormonal parameters, and therefore changes of 
some of these factors may become more apparent before the remodeling changes that 
affect left ventricular volumes.  
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  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-
value 
IC 
Stem 
Cells 
IC 
Serum 
p-
value 
ANOVA 
Ejection 
Fraction 
(%) 
        
Baseline Mean 
(SEM) 
36.0 
(3.423) 
28.90 
(2.373) 
0.0944 32.93 
(4.250) 
41.70 
(3.938) 
0.1411 0.8722/0.1679 
3 month Mean 
(SEM) 
36.64 
(3.212) 
28.68 
(2.312) 
0.0546 38.30 
(3.349) 
40.60 
(3.301) 
0.6285 0.0635/0.8360 
         
p-value 
(Paired 
t test) 
 0.9481 0.6294  0.0138 0.4634   
G-CSF; Granulocyte colony-stimulating factor, SEM; standard error of mean, IC; intracoronary  
Table 11: Primary endpoint results of the REGENERATE-DCM trial: 
change in ejection fraction 
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    Peripheral G-CSF 
Figure 4: Change in ejection fraction in peripheral G-CSF arm 
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     Peripheral Placebo 
Figure 5: Change in ejection fraction in peripheral placebo arm 
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   Intracoronary stem cells 
Figure 6: Change in ejection fraction in intracoronary cell arm 
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Intracoronary serum 
Figure 7: Change in ejection fraction in intracoronary serum arm 
 
 
Baseline 3 months
0
20
40
60
80
E
je
c
tio
n
 F
ra
c
ti
o
n
 (
%
)
P = 0.4634 
87 
 
 
 
 
  Peripher
al G-CSF 
Peripher
al 
Placebo 
p-
value 
IC 
Stem 
Cells 
IC 
Serum 
p-
value 
ANOV
A 
ANOV
A 
Difference in Ejection 
Fraction (%) 
       
Differenc
e 
Mean 
(SEM) 
0.1429 
(2.151) 
-1.071 
(2.168) 
0.694
2 
5.367 
(1.908
) 
-1.100 
(1.459
) 
0.011
9 
0.0433 0.0382 
 
Table 12: REGENERATE DCM trial: Within group difference in ejection 
fraction   
 
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC 
Stem 
Cells 
IC 
Serum 
p-value p-
value 
End Diastolic Volume 
(mls) 
       
Baseline Mean 
(SEM) 
285.1 
(31.80) 
274.0 
(16.90) 
0.7616 253.8 
(31.83) 
226.7 
(21.12) 
0.5799 0.4202 
3 month Mean 
(SEM) 
278.1 
(35.38) 
278.6 
(15.58) 
0.9883 254.2 
(30.16) 
247.3 
(30.24) 
0.8734 0.8156 
         
p-value Paired 
t test 
0.2653 0.9828  0.9793 0.1236   
Table 14: REGENERATE-DCM trial: Change in end-diastolic volume at 
3 months 
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  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-
value 
IC 
Stem 
Cells 
IC 
Serum 
p-
value 
p-
value 
End Systolic Volume (mls)       
Baseline Mean 
(SEM) 
193.3 
(29.51) 
195.1 
(14.11) 
0.9573 176.1 
(27.7) 
139.5 
(22.25) 
0.3114 0.3401 
3 month Mean 
(SEM) 
185.5 
(29.24) 
198.3 
(12.33) 
0.6912 164.7 
(25.53) 
156.9 
(28.52) 
0.8393 0.636 
         
p-value Paired 
t test 
0.2207 0.8210  0.2290 0.0971   
Table 15: REGENERATE-DCM trial: Change in end-systolic volume at 
3 months 
 
 
 
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC 
Stem 
Cells 
IC 
Serum 
p-value p-
value 
Stroke 
Volume 
(mls) 
        
Baseline Mean 
(SEM) 
91.77 
(6.953) 
79.03 
(7.596) 
0.2266 82.03 
(11.81) 
87.07 
(8.134) 
0.7282 0.7506 
3 month Mean 
(SEM) 
92.57 
(8.875) 
80.39 
(8.425) 
0.3288 89.53 
(7.192) 
93.07 
(6.062) 
0.7100 0.6329 
         
p-value Paired 
t test 
0.8728 0.8282  0.4076 0.2752   
Table 16: REGENERATE-DCM trial: Change in stroke volume at 3 
months 
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  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-
value 
IC Stem 
Cells 
IC Serum p-
value 
p-
value 
Myocardial 
Mass (g) 
        
Baseline Mean 
(SEM) 
196.3 
(17.52) 
226.7 
(11.09) 
0.1541 203.6 
(18.65) 
179.9 
(20.35) 
0.3965 0.2938 
3 month Mean 
(SEM) 
214.7 
(19.09) 
236.5 
(14.54) 
0.3714 210.1 
(18.57) 
199.3 
(21.91) 
0.7106 0.5670 
         
p-value Paired 
t test 
0.2152 0.439  0.5707 0.0126   
Table 17: REGENERATE-DCM trial: Change in myocardial mass at 3 
months 
 
 
 
 
 
 
6.4. Progenitor cell (CD34+) mobilisation with G-CSF 
The bone marrow mononuclear cell fraction contains a heterogeneous population of cell 
types which includes hematopoietic progenitor (HSC) cells which are identified by the 
CD34 + marker179,186. The CD34 + HSCs as well as endothelial progenitor cells are 
thought to be the cell types most likely to promote cardiac repair through a number of 
mechanisms including neoangiogenesis, cell fusion and paracrine effect184,185. 
We have previously described how we performed flow cytometry and colony-forming 
unit analysis186. Briefly, HSC populations were identified by incubating cells with the 
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fluorescein isothiocyanate (FITC)-labeled antibody against human CD45 (BD 
Biosciences) and the phycoerythrin (PE)-labeled antibody against human CD34 (BD 
Biosciences) for 15 min at room temperature. EPCs were analyzed by initially 
incubating samples with mouse serum IgG (Sigma) for 15 min at 4 °C with a cocktail of 
antibodies comprising the allophycocyanin-labeled antibody to CD133 (Miltenyi Biotec) 
and the PE-labeled antibody to VEGFR-2 (R&D Systems) to characterize EPCs and 
FITC labeled monoclonal antibodies to CD2, CD13, and CD22 (Beckman Coulter) to 
identify, and therefore, eliminate inclusion of lineage-negative non-progenitor cells. To 
ensure exclusion of nonviable cells in the final EPC count, cells were also incubated 
with a PerCP-Cy5-labeled 7AAD stain (BD Biosciences). Cells were then incubated for 
15 min at room temperature with 2mL of the Pharm Lyse - buffer (BD Biosciences) to 
lyse red blood cells. Samples were washed once in phosphate-buffered saline and 20 
mL of Accucount flow cytometry beads (Saxon Europe) were added before analysis.  
Day 0 PB MNCs (2 x 105 per dish), and Day 6 PB MNCs (2 x 104 per dish) were 
seeded, in triplicate preparations, in methylcellulose plates (Methocult H4534, including 
stem cell factor, granulocyte-macrophage colony stimulating, and interleukin-3, Stem 
cell Technologies). Plates were studied under phase contrast microscopy, and 
granulocyte-macrophage colony- forming units (CFU-GM; colonies > 50 cells) were 
counted after 14 days of incubation. Results were taken from the mean of the triplicate 
results and presented as a ratio of CFU per CD34 cell plated. 
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Effects of G-CSF on mobilization 
Recombinant human G-CSF (Granocyte_; Chugai Pharma) was administered 
subcutaneously at a dose of 10 mg/Kg/day for 5 consecutive days to patients enrolled in 
the REGENERATE-DCM. Patients in the control group received saline injections. A 
peripheral blood sample was obtained on days 0, 1, 2, 3 and 6 for estimation of 
peripheral progenitor cell counts. 
G-CSF treatment led to a significant increase in the peripheral concentration of CD34+ 
cells (day 6 concentration of 56.79 CD34U/mL from baseline of 3.9 CD34U/mL; P < 
0.0001) (figure 5). There was no significant increase in cell concentration in patients 
who received saline injection (day 6 concentration of 4.79 CD34U/mL from baseline of 
4.64 CD34U/mL; P = 0.514) (figure 6). In the G-CSF group, the mean difference in 
CD34+ concentration between day 0 and day 6 was 52.53 CD34U/mL compared to 
0.3629 CD34U/mL in the placebo group (P < 0.0001) (table 6). 
 
 
Effects of disease state on CD34+ function and number 
When compared to patients with ischemic heart disease (IHD), DCM patients had a 
higher concentration of peripheral blood CD34+ (3.4 ± 2.1 CD34 + U/ μL vs. 2.6 ± 1.9 
CD34 + U/ μL, P = 0.033). The increase in CD34+ concentration post 5 days of G-CSF 
injection was comparable in DCM and IHD patients186. This is consistent with previous 
reports showing circulating EPCs inversely correlate with number of risk factors for 
coronary artery disease187. Although there was a higher concentration of circulating 
CD34 + cells in DCM patients, the CFU analysis suggested that there was no difference 
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in functional capability186,258-260.  
In both DCM and IHD patients, we found an inverse relationship between age and 
peripheral blood CD34 + cell concentration. Older patients had a lower concentration of 
CD34 + cells in the bone marrow following mobilization with G-CSF (75.49 – 64.49 
CD34 U/mL vs. 113.5 – 61.03, P = 0.0023). There was also a trend (P = 0.09) toward 
lower percentage increase in circulating CD34 + cells (day 6 compared to day 0) with G-
CSF in those aged above 64 years186,261. 
The difference in circulating progenitor cells between IHD and DCM has not previously 
been demonstrated. Our findings suggest that the atherosclerotic process rather than 
chronicity or severity of disease is the important determinant of the progenitor cell 
concentration. 
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Figure 8: REGENERATE-DCM trial: Change in CD34+ in the peripheral 
and intervention G-CSF arm  
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Figure 9: REGENERATE-DCM trial: Change in CD34+ in the placebo 
arm  
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  All G-CSF Arms Placebo p-value 
CD34
+ 
(uL-1)     
Baseline Mean (SEM) 3.939 (0.5340) 4.637 (0.8549) 0.5140 
6 days Mean (SEM) 56.79 (6.658) 4.795 (0.7835) < 0.0001 
P-value Paired t test < 0.0001 0.5791  
CD34
+ 
(uL-1)    
Difference Mean (SEM) 52.53 (6.695) 0.3629 
(0.6378) 
< 0.0001 
SEM; Standard error of mean 
Table 13: REGENERATE-DCM trial: CD34+ concentration at baseline 
and 6 days in the G-CSF and placebo arms 
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6.5. Effect of intracoronary stem cell therapy on heart failure and    
angina symptoms  
The change in New York Heart Association (NYHA) heart failure symptoms at 3 months 
in the 4 groups is summarised in tables 12 and 13.  There was no significant difference 
in NYHA functional classification at baseline between the 4 groups (Mean 2.07, P = 
0.2). There was no significant change in NYHA functional class at 3 months in the 
peripheral placebo, peripheral G-CSF and intracoronary serum groups. In the peripheral 
placebo group, the mean NYHA increased from 2.4 at baseline to 2.429 at 3 months 
(P=0.08), and in the peripheral G-CSF group decreased from 2.267 at baseline to 2.0 at 
3 months (P=0.3). In the intracoronary serum group, the mean NYHA was 2.3 at 
baseline and 3 month follow-up (P>0.99). There was however, a significant 
improvement in heart failure symptoms in the intracoronary stem cell group with a 
reduction of NYHA functional class from 2.6 at baseline to 2.067 at 3 months 
(P=0.0061).  Six patients (40%) in the intracoronary stem cell group had an 
improvement by 1 stage in NYHA functional classification (5 patients improved from 
NYHA 3 to 2, and one patient form NYHA 3 to1). None of the patients in the 
intracoronary stem cell group had worsening of their symptoms at 3 month follow-up. In 
the intracoronary placebo group, 1 (6.7%) of the patients had a reduction in NYHA 
functional class from 2 to1, and 4 (26.7%) patients had worsening of their symptoms 
from NYHA 2 to 3. None of the patients in the peripheral placebo group had an 
improvement in functional class, while 1 (7.1%) patient’s symptom worsened from 
NYHA 2 to 3. By comparison, 3 (21.4%) patients NYHA functional class improved (2 
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patients improved from NYHA 2 to 1, and 1 patient from NYHA 3 to 2), and 1 patients 
symptoms worsened form NYHA 2 to 3.  
There was a significant within group improvement in symptoms in the intracoronary 
stem cell group that was not seen in any of the other groups. 
A significant proportion of patients had angina at baseline (6.7%, 33.3%, 40% and 20% 
in the peripheral G-CSF, peripheral placebo, intracoronary stem cells and intracoronary 
serum respectively; P= 0.29) (table 3). There was a significant within group 
improvement in angina symptoms (mean reduction of CCS classification of 0.33) in the 
intracoronary stem cell group compared to the 3 other groups (P= 0.029) (table 14).  
 
 
Figure 10: REGENERATE-DCM trial: Change in NYHA functional class 
 
Figure legend: Total number (15 in each group; -5 to 10) and % of patients that had a change in NYHA 
functional class in each group. 
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Table 18: REGENERATE-DCM trial: Mean change in NYHA functional 
class 
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-
value 
IC Stem 
cell 
IC  
Serum 
p-
value 
ANOVA 
NYHA         
Baseline Mean 
(SEM) 
2.267 
(0.1182) 
2.400  
(0.1309) 
0.456 2.600 
(0.1633) 
2.333 
(0.1260) 
0.2066 0.5125 
3 month Mean 
(SEM) 
2.000 
(0.1482) 
2.429 
(0.1373) 
0.0436 2.067 
(0.2063) 
2.333 
(0.2108) 
0.3736 0.3007 
 p-
value 
0.3356 0.0823  0.0061 > 
0.9999 
  
NYHA       p-
value 
IC 
arms 
 
Difference Mean 
(SEM) 
-0.1429 
(0.1429) 
0.07143 
(0.07143) 
 -0.4667 
(0.1652) 
0.2000 
(0.1447) 
0.0052  
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Table 19: REGENERATE-DCM trial: Mean change in CCS functional 
class 
  Peripheral 
G-CSF 
Peripheral 
Placebo 
IC Stem 
cell 
IC  
Serum 
Chi Sq 
CCS       
Improved Number 
(%) 
0 (0%) 1 (7.1%) 3 (20%) 0 (0%) 0.1234 
Unchanged Number 
(%) 
13 
(92.9%) 
10 (21.4%) 12 (80%) 12 (80%) 10.03, 6 
Worsened Number 
(%) 
1 (7.1%) 3 (21.4%) 0 (0%) 3 (20%)  
       
CCS      P-value IC arms 
Difference Mean 
(SEM) 
0.1333 
(0.1333)  
0.07143 
(0.1951) 
-0.3333 
(0.2108) 
0.2667 
(0.1533) 
0.029 
 
 
6.6. Change in BNP at 3 months 
The baseline bloods were similar between the 4 groups (table 15). The mean plasma B-
type Natriuretic Peptide (BNP) at baseline was 1346 pg/ml with no significant difference 
between the 4 groups (P=0.7). The high level of BNP at baseline is a marker of the 
severity of heart failure in this cohort of patients. Despite an improvement in ejection 
fraction, there was no significant change in BNP at 3 months in the intracoronary stem 
cell group (964.7 baseline, 1106 at 3 months; P=0.67). However, in one of the patients, 
the BNP increased from 1548 to 6050. This patient was admitted to hospital with an 
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acute exacerbation of Gout and deranged liver function prior to his 3 month follow-up, 
which likely would have accounted for the otherwise unexplained increase in BNP. His 
ejection fraction increased from 20% to 25% at 3 months. When this patient is removed 
from the BNP analysis, we found a trend towards a significant reduction in 3 month BNP 
in the intracoronary stem cell group from 964.7 to 752.7 (P= 0.0565), and an inverse 
correlation between plasma BNP levels and ejection fraction (figure 7). 
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  Periphera
l G-CSF 
Periphera
l Placebo 
p-
value 
IC 
Stem 
Cells 
IC 
Serum 
p-
value 
ANOV
A 
ANOV
A 
BNP          
Baselin
e 
Mean 
(SEM) 
1640 
(508.1) 
1303 
(318.6) 
0.579
2 
964.7 
(240) 
1474 
(566.7
) 
0.403
9 
0.8163 0.6447 
3 
month 
Mean 
(SEM) 
1411 
(517.8) 
1424 
(400.7) 
0.983
4 
1106 
(408.1
) 
1124 
(394.7
) 
0.974
5 
0.9994 0.8432 
p-value Paire
d t 
test 
0.1447 0.7619  0.6665 0.2094    
Table 20: REGENERATE-DCM trial: Change in plasma B-type 
Natriuretic Peptide (BNP) 
 
 
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-
value 
IC 
Stem 
Cells 
IC 
Serum 
p-
value 
ANOVA ANOVA 
BNP          
Baseline Mean 
(SEM) 
1640 
(508.1) 
1303 
(318.6) 
0.5792 964.7 
(240) 
1474 
(566.7) 
0.4039 0.8163 0.6447 
3 month Mean 
(SEM) 
1411 
(517.8) 
1424 
(400.7) 
0.9834 752.7 
(219.7) 
1124 
(394.7) 
0.427 0.4254 0.7584 
p-value Paired 
t test 
0.1447 0.7619  0.0565 0.2094    
Table 21: REGENERATE-DCM trial: Change in plasma B-type 
Natriuretic Peptide (BNP) after removal of outlier in the IC stem cell 
group 
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Figure 11: REGENERATE-DCM trial: Ejection fraction correlation with  
B-type Natriuretic Peptide (BNP) 
 
6.7. Changes in exercise functional capacity at 3 months 
 
Patients with chronic heart failure have a reduced maximal exercise capacity 
characterized by the reduction in oxygen consumption at peak exercise262. 
Determination of VO2 max (which determines the limits of the cardiopulmonary system) 
during exercise has been shown to predict prognosis in these patients 263. 
When VO2max was ≤14.5 ml/kg per min, survival rates were significantly less than in 
patients with VO2max >14.5 ml/kg per min263, and patients who achieve > 50% 
predicted VO2 max have an excellent short-term prognosis264.  
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The mean peak VO2 in our cohort of patients at baseline was 18.7 ml/kg/min. This is 
probably due to the fact that the patients were young (mean age 54) and therefore had 
a good exercise threshold. The mean peak VO2 increased to 19.2 ml/kg/min at 3 
months with no significant difference observed between the 4 groups. However, 13 
patients failed to reach peak exercise threshold at baseline and 6 patients failed to 
reach peak exercise threshold at 3 months, an additional 2 patients withdrew and 1 
patient was not allowed to perform the test due to clinical issues. Therefore a total of 22 
patients (36.6%) failed to have appropriate paired testing. The baseline mean peak VO2 
in the peripheral G-CSF group was 18.8 (64.47% predicted), which increased to 19.16 
(66.85 % predicted) at 3 months, and the mean baseline peak VO2 in the peripheral 
placebo group was 18.9 (66.21 % predicted), which increased to 17.9 (73.64 % 
predicted) at 3 months (P=NS). The mean baseline peak VO2 in the IC stem cell group 
was 17.6 (60.21 % predicted), which increased to 19.1 (63.33 % predicted) at 3 months, 
and the mean baseline peak VO2 in the IC serum group was 19.5 (69.93% predicted), 
which increased to 20.6 (73.64 % predicted) at 3 months (P=NS) (Tables 17 and 18). 
The mean baseline VE/VCO2 in the peripheral G-CSF group was 32.4 which increased 
to 31.3 at 3 months, and the mean baseline VE/VCO2 in the peripheral placebo group 
was 36.1 which increased to 38.2 at 3 months; P=NS. The mean baseline VE/VCO2 in 
the IC stem cell group was which increased to 39.6 at 3 months, and the mean baseline 
VE/VCO2 in the IC serum group was 32.9 which increased to 34 at 3 months; P=NS. 
Furthermore, comparison of the changes in the exercise parameters at baseline and 3 
months showed no significant difference between the 4 groups.  
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As maximum effort is not always achieved during exercise testing, a widely used 
submaximal index of exercise capacity is the anaerobic threshold (AT). AT usually 
occurs between 45%-65% of measured peak VO2, but it occurs lower in patients with 
heart failure265. Measurement of anaerobic threshold (AT) during exercise testing is 
based on the principle that energy production shifts from an aerobic metabolism to a 
metabolism that combines both anaerobic and aerobic patterns during a progressively 
increasing workload exercise. The value of oxygen uptake at AT has been used to 
assess the severity of heart failure266 as it is independent of patients motivation and 
exercise duration267. However, AT is not identifiable in a large proportion of patients with 
heart failure268, and this is associated with a worse prognosis269.  
The mean baseline anaerobic threshold (AT) in the peripheral G-CSF group was 12.8 
which increased to 14.1 at 3months, and the mean baseline AT in the peripheral 
placebo group was 12.8 which reduced to 12.4 at 3 months; P=NS. The mean baseline 
AT in the IC stem cell group was 12.8 which reduced to 12.2 at 3 months, and the mean 
baseline AT in the IC stem cell group was 13.99 which reduced to 12.3; P=NS. 
Achievement of ≥ 85% of maximal age-predicted target heart is a well-recognized 
indicator of sufficient subject effort during exercise. However, the variability of maximal 
heart rate and the wide use of B-blockers in heart failure population undermine the 
effectiveness of to gauge subject effort by their heart response alone. The peak 
respiratory exchange ratio (RER), defined as carbon dioxide production divided by 
oxygen consumption, is used to quantify exercise exertion level and obviates the need 
to assess the subjects heart rate..  It is the most accurate and reliable gauge of exercise 
effort266. A peak RER of ≥ 1.10 is considered a universal indicator that reflects maximal 
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exertion independent of patient characteristics such as age, sex, fitness, and disease 
state. Achievement of a peak RER <1.00 that is terminated by subject request, in the 
absence of any electrocardiographic or hemodynamic abnormalities, generally reflects 
submaximal cardiovascular effort266. A significant change in exercise capacity after 
specific intervention with similar peak RER values suggests that the observed changes 
are secondary to the intervention used. Exercise duration (i.e. the number of minutes 
the subject can continue on the exercise treadmill) is a good measure of the functional 
capacity and is a predictor of mortality. In fact, of the prognostic variables measured 
during exercise treadmill testing, exercise duration is the strongest270,271. Exercise 
duration decreases with age and is lower in women compared to men, but it retains its 
prognostic value after adjusting for age and sex. Functional capacity can be measured 
by measuring oxygen uptake during exercise, which can be converted to metabolic 
equivalents (METs): 1 MET = 3.5 mL O2/kg/min. In patients with ischemic heart disease 
post revascularization, exercise capacity has been found to be the most powerful 
predictor of subsequent outcome, particularly mortality. For every 1MET increase there 
was a 27% reduction in mortality272.  
In the REGENERATE-DCM trial, there was a significant improvement in exercise 
duration at 3 months in the intracoronary stem (IC) cell group compared to the 
intracoronary serum group. The mean baseline exercise time (ET) at baseline in the IC 
serum group was 477.1 seconds (s) compared to 424.1s in the IC stem cell group (P = 
0.43). At 3 months, the mean ET in the IC serum group increased to 506.7s, compared 
to 504s in the IC stem cell group. The mean increase in ET was significantly higher in 
the IC stem cell group (P= 0.0146). There was no significant difference in the mean ET 
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between the 2 peripheral groups; baseline mean ET 476.9s and 458.3s in the GCSF 
and placebo groups respectively, which increased to 460.4s and 402.9s at 3 months ( 
P= 0.1368). The difference in oxygen consumption at 3 months was  -1.9, -4.9, -3.5 and 
+8.2 METs in the peripheral G-SCF, peripheral placebo, IC serum and IC stem cells 
respectively. Although there was a trend towards to an improvement in oxygen 
consumption (MET) in the IC stem cell group, this did not reach statistical significance.  
 
 
 
Peak VO2  
(ml/kg/min) 
Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value 
Baseline Mean 
(SEM) 
18.83 
(1.400) 
18.99 
(0.9087) 
0.9226 17.67 
(1.488) 
19.55 
(1.816) 
0.4316 
3 month Mean 
(SEM) 
19.16 
(1.642) 
17.97 
(0.9487) 
0.5398 19.13 
(1.940) 
20.61 
(2.442) 
0.638 
        
P-value Paired t 
test 
0.5834 0.2181  0.1677 0.2571  
 
Table 22: REGENERATE-DCM trial: Change in VO2 max at 3 months 
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  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-
value 
IC Stem 
Cells 
IC Serum p-value 
VO2 % predicted 
(%) 
      
Baseline Mean 
(SEM) 
64.47 
(5.142) 
66.21 
(4.648) 
0.8038 60.21 
(4.302) 
69.93 
(4.638) 
0.1375 
3 month Mean 
(SEM) 
66.85 
(6.676) 
63.54 
(4.646) 
0.6879 63.33 
(6.159) 
73.64 
(6.377) 
0.255 
        
P-value Paired 
t test 
0.9444 0.4303  0.3437 0.1211  
Table 23: REGENERATE-DCM trial: Change in VO2% predicted at 3 
months 
 
 
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value 
VE/VCO2        
Baseline Mean 
(SEM) 
32.47 
(1.788) 
36.17 
(2.592) 
0.2443 34.86 
(2.469) 
32.93 
(1.572) 
0.5107 
3 month Mean 
(SEM) 
31.29 
(1.450) 
38.23 
(3.207) 
0.0539 39.60 
(4.232) 
34.00 
(1.541) 
0.2371 
        
p-value Paired 
t test 
0.4297 0.1114  0.1359 0.2042  
Table 24: REGENERATE-DCM trial: Change in VE/VCO2 at 3 months 
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  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value 
Anaerobic Threshold 
(mls/kg/min) 
     
Baseline Mean 
(SEM) 
12.82 
(0.9203) 
12.86 
(0.9869) 
0.9791 12.81 
(0.7933) 
13.99 
(1.215) 
0.4477 
3 
month 
Mean 
(SEM) 
14.12 
(1.354) 
12.43 
(1.478) 
0.4127 12.21 
(1.326) 
12.34 
(1.506) 
0.9479 
        
p-value Paired 
t test 
0.3796 0.4855  0.9522 0.0952  
Table 25: REGENERATE-DCM trial: Change in Anaerobic Threshold at 
3 months 
 
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value 
Saturations (%)       
Baseline Mean 
(SEM) 
97.80 
(0.3928) 
98.00 
(0.3780) 
0.7173 98.93 
(0.2282) 
97.93 
(0.1533) 
0.0011 
3 
month 
Mean 
(SEM) 
97.43 
(0.3882) 
97.69 
(0.2083) 
0.5635 98.53 
(0.3065) 
98.36 
(0.3249) 
0.6961 
        
p-value Paired 
t test 
0.6198 0.5016  0.2711 0.2123  
Table 26: REGENERATE-DCM trial: Change in Oxygen saturation at 3 
months 
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Peripheral 
G-CSF 
Peripheral 
Placebo p-value 
IC Stem 
Cells IC Serum p-value ANOVA ANOVA 
Peak VO2 
(ml/kg/min) 
        
Difference 
Mean 
(SEM) 
0.5143 
(0.9145) 
-1.092 
(0.8404) 0.2097 
1.460 
(1.003) 
0.9143 
(0.7712) 0.6729 0.0961 0.8861 
          VO2 % predicted 
(%) 
        
Difference 
Mean 
(SEM) 
0.2308 
(3.239) 
-2.462 
(3.016) 0.5487 
3.857 
(3.925) 
3.929 
(2.368) 0.9877 0.308 0.9998 
          
VE/VCO2 
         
Difference 
Mean 
(SEM) 
-0.6429 
(0.7887) 
2.046 
(1.191) 0.0678 
7.067 
(3.592) 
1.071 
(0.8015) 0.1264 0.1813 0.0851 
          Anaerobic Threshold 
(mls/kg/min) 
       
Difference 
Mean 
(SEM) 
0.8727 
(0.9494) 
-0.8917 
(1.235) 0.2765 
-0.07273 
(1.184) 
-1.821 
(1.012) 0.2712 0.8479 0.4551 
          Saturations (%) 
        
Difference 
Mean 
(SEM) 
-0.2143 
(0.4216) 
-0.1538 
(0.2221) 0.9023 
-0.4000 
(0.3491) 
0.4286 
(0.3267) 0.0957 0.8508 0.1668 
 
 
Table 27: REGENERATE-DCM trial: Differences in Peak VO2, VO2% 
predicted, VE/VCO2, Anaerobic Threshold and oxygen saturation 
between baseline and 3 months 
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Exercise time 
Peripheral 
G-CSF 
Peripheral 
Placebo p-value 
IC Stem 
Cells IC Serum p-value ANOVA ANOVA 
Baseline 
Mean 
(SEM) 
476.9 
(39.39) 
458.3 
(35.23) 0.7275 
424.1 
(47.30) 
477.1 
(47.60) 0.4368 0.8181 0.6212 
3 month 
Mean 
(SEM) 
460.4 
(52.41) 
402.9 
(53.89) 0.451 
504.0 
(61.70) 
506.7 
(59.17) 0.9753 0.383 0.9993 
          
p-value 
Paired 
t test 0.6836 0.1368 
 
0.0146 0.4471 
   
          
  
Peripheral 
G-CSF 
Peripheral 
Placebo p-value 
IC Stem 
Cells IC Serum p-value ANOVA ANOVA 
Exercise time 
difference 
        
Difference 
Mean 
(SEM) 
-16.53 
(39.73) 
-55.40 
(35.10) 0.4696 
79.87 
(28.68) 
29.60 
(37.84) 0.2988 0.0188 0.5405 
 
s 
Table 28: REGENERATE-DCM trial: The difference in exercise duration 
at baseline and 3 month 
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6.8. Secondary Endpoint: Quality of life 
I used the EQ5D and the VAS questionnaires to assess our patients Quality of life at 
baseline and at 3 months. The EuroQOL five dimensions questionnaire (EQ-5D) is one 
of the most commonly used generic questionnaires to measure health-related quality of 
life, which encompasses both positive (well-being) and negative aspects (illness). It 
consists of a questionnaire and a visual analogue scale (EQ-VAS). The EQ-5D is a self-
reported description of the subject’s current health in 5 dimensions that include mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 
3 levels: no problems, some problems, severe problems. The respondent is asked to 
indicate his/her health state by ticking in the box against the most appropriate statement 
in each of the 5 dimensions. This decision results in a 1-digit number expressing the 
level selected for that dimension. The EQ-VAS records the subject’s perceptions of their 
own current overall health and can be used to monitor changes with time. It records the 
respondent’s self-rated health on a vertical, visual analogue scale where the endpoints 
are labeled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This 
information can be used as a quantitative measure of health outcome as judged by the 
individual respondents.   
In the REGENERATE-DCM trial, we found no significant change in the quality of life as 
judged by the EQ-5D and VAS questionnaires (tables 23 and 24). 
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EQ5D Index Score Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value p-
value 
p-
value 
Baseline Mean 
(SEM) 
0.4915 
(0.08969) 
0.6753 
(0.08192) 
0.1415 0.5748 
(0.06290) 
0.7311 
(0.05716) 
0.0762 0.5761 0.2728 
3 month Mean 
(SEM) 
0.6665 
(0.07500) 
0.6847 
(0.09520) 
0.8849 0.5492 
(0.07536) 
0.6901 
(0.06313) 
0.1605 0.3962 0.3439 
          
p-value Paired  
t test 
0.1194 0.8408  0.6541 0.5056    
          
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem 
Cells 
IC Serum p-value p-
value 
p-
value 
EQ5D Index Score         
Difference Mean 
(SEM) 
0.1132 
(0.06647) 
0.01315 
(0.06409) 
0.2923 -0.03008 
(0.06546) 
-0.0410 
(0.06000) 
0.9029 0.8666 0.9902 
 
Table 29: REGENERATE-DCM trial: EQ5D Index score at baseline and 
3 months  
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  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem Cells IC Serum p-value p-
value 
 
VAS           
Baseline Mean 
(SEM) 
55.07 
(5.464) 
57.27 
(4.096) 
0.7497 53.21 (3.997) 56.93 
(4.126) 
0.5238 0.7773 0.5941 
3 month Mean 
(SEM) 
67.73 
(4.489) 
57.08 
(3.574) 
0.0735 58.46 (5.948) 60.07 
(4.100) 
0.8222 0.8815 0.8154 
          
p-value Paired 
t test 
0.2553 0.4900  0.4308 0.3139    
          
  Peripheral 
G-CSF 
Peripheral 
Placebo 
p-value IC Stem Cells IC Serum p-value p-
value 
p-
value 
VAS          
Difference Mean 
(SEM) 
7.636 
(6.328) 
2.385 
(3.348) 
0.4515 4.231 (5.189) 3.133 
(3.000) 
0.8514 0.9469 0.9795 
          
 
Table 30: REGENERATE-DCM trial: EQ5D Index score at baseline and 
3 months  
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6.9. Results of the Biomarker sub-study 
I measured the pro-inflammatory cytokines detailed in this section in all 4 groups 
at day 0 and day 6. There was no significant change in the plasma levels of the 
cytokines at these time points (graphs below).  
 
Figure 12A: REGENERATE-DCM trial: Change in plasma IL-2 at day 0 
and day 6 in the peripheral G-CSF and placebo group 
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Figure 12B: REGENERATE-DCM trial: Change in plasma IL-6 at day 0 
and day 6 in the peripheral G-CSF and placebo group 
 
 
Figure 12C: REGENERATE-DCM trial: Change in plasma IL-8 at day 0 
and day 6 in the peripheral G-CSF and placebo group 
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Figure 12D: REGENERATE-DCM trial: Change in plasma IL-10 at day 0 
and day 6 in the peripheral G-CSF and placebo group 
 
 
 
Figure 12E: REGENERATE-DCM trial: Change in plasma IL-1A at day 0 
and day 6 in the peripheral G-CSF and placebo group 
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Figure 12E: REGENERATE-DCM trial: Change in plasma EGF at day 0 
and day 6 in the peripheral G-CSF and placebo group 
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Figure 12F: REGENERATE-DCM trial: Change in plasma IL-1B at day 0 
and day 6 in the peripheral G-CSF and placebo group 
 
 
 
Figure 12G: REGENERATE-DCM trial: Change in plasma TNF-A at day 
0 and day 6 in the peripheral G-CSF and placebo group 
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Figure 12H: REGENERATE-DCM trial: Change in plasma IFNG at day 0 
and day 6 in the peripheral G-CSF and placebo group 
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Figure 12 I: REGENERATE-DCM trial: Change in plasma VEGF at day 0 
and day 6 in the peripheral G-CSF and placebo group 
 
 
 
Figure 12 J: REGENERATE-DCM trial: Change in plasma IL-4 at day 0 
and day 6 in the peripheral G-CSF and placebo group 
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6.10. Trial Safety: 
There were no MACE events recorded during intracoronary injection of stem cells or 
saline. One patient experienced chest pain and ECG changes and one patient 
experienced dissection of the right coronary artery during intracoronary infusion of stem 
cells. This required treatment with a coronary stent with no further adverse sequelae.  
Both intracoronary events did not reach protocol stated rise in CK to be ruled as 
myocardial infarction. There were no significant differences in reported serious adverse 
events, adverse events or hospital admissions between the 4 groups. 
 
 
Figure 12: REGENERATE-DCM trial: Serious adverse events 
(SAE), adverse events (AE) and hospital admissions 
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7. DISCUSSION 
This is the first randomised trial in DCM assessing the use of bone marrow derived stem 
cells and adjunctive G-CSF to demonstrate a significant increase in cardiac function 
both within the intracoronary stem cell treated patients and in comparison to an 
interventional placebo control.  The trial is also unique in that compared to the 
interventional control group it demonstrated a 5.47% increase in LVEF in the 
intracoronary stem cell group at 3 months. This LVEF improvement was associated with 
significant improvements in the clinical parameters of NYHA class and exercise 
capacity. The remaining treatment groups (intracoronary serum, G-CSF alone and 
peripheral placebo) showed no evidence of improvement in any of the end-points at 3 
months. These results therefore demonstrate the beneficial effects across multiple 
clinical and intermediate parameters of autologous cell and adjunctive cytokine therapy 
in a randomised control trial of patients suffering from dilated cardiomyopathy. 
Similar beneficial effects on cardiac function with BMC therapy have been shown in 
other early phase studies144,273, with the most recent demonstrating improvements out 
to 5 years post therapy274. However no study has been performed with an interventional 
control group blinded to the investigators. Previous studies have also used G-CSF as a 
cell mobilising factor but few have controlled for the possibility that this cytokine may 
have a direct effect on cardiac function as has been previously suggested165,275. Early 
preclinical and initial Phase I trials suggested that G-CSF administration was safe and 
possibly associated with improvements in LVEF168. The REGENERATE DCM is 
therefore the first trial designed with a separate interventional and cytokine control 
group.  
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Dilated cardiomyopathy is characterized by ventricular dilatation and reduced 
myocardial-wall thickness which results in an increase in myocardial-wall stress 
159,162,276. Left-ventricular end-diastolic volumes did not decrease; indicating that transfer 
of bone-marrow-cells did not improve left-ventricular remodeling at 3 months. In patients 
with heart failure, cardiac dysfunction can be progressive even in the absence of 
change in symptoms. A fall in ejection fraction (EF) is an independent predictor of 
mortality. The Vasodilator-Heart Failure Trials (V-HeFT I and V-HeFT II) identified EF as 
a powerful predictor of all-cause mortality in HF patients263,277, and improvement in EF 
has ben linked to improved prognosis258-260,278. Even patients with asymptomatic LV 
dysfunction are at an increased risk of sudden cardiac death261. While serial 
measurement of EF provides important prognostic information277, other additional 
effects of therapy should be taken into consideration such as changes in plasma BNP, 
cardiac remodeling and improvement in exercise functional capacity. Preventing chronic 
progression of heart failure by slowing or reversing the remodeling process should be a 
target for novel therapies of heart failure278. Heart failure therapies that had an impact 
on morbidity and mortality, such as B-blockers and ACE inhibitors, had a positive impact 
on LV remodeling and EF163,166,279-283. However these changes were only apparent after 
6 months of initiating therapy283,284. A sub-study from CIBIS I showed that although 
Bisoprolol improved EF and reduced end-systolic dimensions after 5 months therapy, it 
had no significant effect on LV end- diastolic dimensions285. 
Changes in cardiac remodeling is a slow process and should be assessed after at least 
4 months of initiating therapy278. This, partly, explains the lack of improvement of LV 
end-systolic and end-diastolic volumes in the REGENERATE-DCM trial despite the 
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improvement in EF.  
BNP significantly correlates with NYHA classification. BNP was more closely correlated 
with mortality than NYHA functional class and ejection fraction. Koglin et al studied 78 
CHF patients in a multivariable prognostic model to monitor the clinical course and 
outcomes for 398 days.18 Parameters assessed included BNP and variables used to 
develop the heart failure survival score (HFSS), which include LVEF, resting heart rate, 
mean blood pressure and intraventricular conduction volume. Changes in BNP level 
were significantly related to changes in physical activity and prediction of survival status 
and was as powerful as the HFSS. BNP has also been used to identify heart failure 
patients at high risk of death or hospitalization286. Plasma BNP concentrations are 
higher in patients with more severe symptoms and in those with more severe cardiac 
damage287, and is an independent predictor of death in patients with chronic heart 
failure 211. BNP correlates well with cardiopulmonary exercise capacity and with 
composite measures of heart failure severity, such as the Heart Failure Survival 
Score288. After initiating treatment, there is a correlation between an improvement in 
functional status and the reduction in plasma BNP levels. BNP also plays an important 
role in risk stratifying patients with advanced heart failure selected for heart 
transplantation288. In patients taking B-blockers, BNP is a better prognostic predictor 
than more traditional parameters such as peak VO2210. Data on 128 consecutive 
patients who were taking beta-blockers and were awaiting transplantation show that the 
only independent predictor of all cause mortality was an NT-proBNP value above the 
median of 1498 pg/ml. A study involving 452 patients with left ventricular dysfunction 
with a high rate of sudden death found that the BNP concentration was the only 
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independent predictor of sudden death209. However, there is a wide variation of plasma 
BNP levels as it relies on various factors such as age, renal function, left ventricular 
ejection fraction and left ventricular filling pressure. Furthermore, renal function tends to 
deteriorate with progression of heart failure and stepping up diuretic therapy, which 
results in a progressive rise in plasma BNP levels289. Therefore using serial BNP as a 
guide to response to therapy is complicated and should take into consideration other 
factors that raise plasma BNP such as worsening renal function. Furthermore, in a 
Cleveland Clinic study, a wide variation of plasma BNP levels were observed in patients 
admitted for decompensated heart failure requiring haemodynamically guided therapy. 
In particularly some of the patients with idiopathic dilated cardiomyopathy had BNP 
levels in the lower ranges (≤ 100 pg/mL)290. A more recent observational study has 
shown that 6-month post-discharge BNP was closely associated with long-term 
outcome, but BNP at 3 months as well as at discharge was not predictive of it291. In this 
study readmitted patients, in contrast to event-free patients, showed an increase in BNP 
levels despite clinical stabilization and had no improvement in echocardiographic 
parameters during the 6 months follow-up. The authors concluded that an increase in 6-
month (but not 3-month) post-discharge BNP before clinical evidence of 
decompensation in part reflects a poor reverse LV remodeling, and therefore BNP 
measurement at 6-mponth post treatment may have a role as a therapeutic guide291.  
In the REGENERATE-DCM trial, the mean plasma B-type Natriuretic Peptide (BNP) at 
baseline was 1346 pg/ml. The high level of BNP at baseline is a marker of the severity 
of heart failure in this cohort of patients. Despite an improvement in ejection fraction, 
there was a trend towards a significant reduction in 3 month BNP in the intracoronary 
127 
 
 
stem cell group, but this did not reach statistical significance. The small sample size and 
short time frame (3 months) may have accounted for lack of significant change in 
plasma BNP levels. We hypothesized that administration of G-CSF to patients in the 
REGENERATE-DCM trial will lead to a reduction in pro-inflammatory cytokines, and 
injection of autologous BMMNC will confer an additional reduction above that derived 
from G-CSF injection alone. However, there was no significant reduction in the 
cytokines at day 6 in either the G-CSF or stem cell group compared to placebo. 
Unfortunately, I was unable to measure the plasma pro-inflammatory cytokines at 3 
month follow-up. Given the lack of significant reduction in BNP levels at 3 months, it 
would seem unlikely that G-SCF or intracoronary stem cells would have resulted in a 
reduction in the pro-inflammatory biomarkers during the same timeframe.  
The study population enrolled in REGENERATE DCM is typical of a DCM population, 
with similar baseline characteristics and medical therapy to patients in other published. 
The biochemical markers indicating severity of heart failure were similar across all 
groups with a NT-proBNP level greater than 1000 pg/ml suggestive of significant left 
ventricular dysfunction. The REGENERATE DCM patient population had high levels of 
optimal medical therapy in all groups and were stabilised prior to randomisation. The 
improvement in cardiac function and symptoms in the cell treated group was thus 
unlikely to be due to differences in medical therapy between the groups. The 
REGENERATE DCM patient population also had appropriate levels of ‘device therapy’ 
in keeping with current American Heart Association guidelines and consistent between 
groups. The results of the REGENERATE-DCM trial demonstrate a significant 
improvement in left ventricular function and an improvement in symptoms and exercise 
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capacity. Further investigation using similar methodology in a Phase III trial is needed to 
assess whether cell therapy lead to a prognostic benefit in these patients to accompany 
the functional changes seen. 
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8. CONCLUSION: 
The intracoronary infusion of autologous bone marrow derived mononuclear cells in 
combination with G-CSF therapy in patients with DCM appears to be safe and is 
associated with an improvement in LVEF 3 months after therapy. These functional 
differences were accompanied by improvement in a panel of biochemical and symptom 
related outcomes supporting a real clinical effect. 
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9. CONCLUSIONS AND FUTURE DIRECTIONS 
There has been quite a rapid translation of stem/progenitor cell research from preclinical 
to human trials, which answered many questions but also highlighted the current 
limitations. This rapid translation is partly because BMC transplantation is easy for 
clinical application owing to its simplicity and autologous model, negating the problems 
of ethics and immune rejection. The REGENERATE-DCM in conjunction with other 
trials has demonstrated the safety and efficacy of stem cell and cytokine therapy in the 
treatment of myocardial cell loss. However, criticism of the rapid translation of this novel 
therapy has been the lack of precise characterization of the cells injected, measurement 
of the efficiency of cell uptake and engraftment by the heart and assessment of bio-
distribution and elimination of cells from the body. Hence, further work aimed 
specifically at defining bio-distribution and cellular kinetics will be crucial to the rational 
design of future clinical trials and the eventual safe application of cell therapy in the 
clinical setting.  
Great progress has been made but the field remains unclear regarding cell type, cell 
number and injection method as well as understanding fully which groups of patients to 
target. The situation has not been helped by the heterogeneity of trial design and the 
diversity of techniques used. There is no universally accepted standardized method to 
process cells (although regulatory issues apply) and the only consensus document 
regarding trial design was published by the ESC task force in 2006292. The question of 
standardization for BMSC processing should be addressed in the next five years 
following the EU award of funding to conduct a 3,000 patient mortality trial of BMSC in 
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AMI (BAMI Consortium). Standardization of techniques is a key component of this 
award. It is hoped that this Phase III trial will answer the questions which have arisen 
from the smaller Phase I/II clinical trials of BMSC that have been published to date. Its 
primary endpoint will address whether BMSC therapy reduces mortality in AMI.  
Strategies are also needed to understand the mechanisms involved in stem cell and 
cytokine therapy, and the interactions between the stem cells and the local environment 
to improve the cells’ homing abilities and enhance their survival. Both animal and 
clinical studies in DCM have demonstrated that stem cells do not transdifferentiate into 
cardiomyocytes, suggesting that a paracrine effect with stimulation of vasculogenesis 
and cell proliferation as a potential important mechanism of stem cells in cardiac 
remodeling and improvement in cardiac status. In conjunction with basic science 
research, further large randomized trials are needed to assess the efficacy of this 
treatment and its long-term effect on cardiac function, survival and quality of life.  
Many challenges lie ahead, including the need to identify the right patient who is likely to 
benefit from this therapy. The REGENERATE-DCM trial, which included patients with 
no other treatment option, was a good logical starting point as these the subset of 
patient that are most likely to benefit from this therapy. We have demonstrated the 
safety of cell therapy for intracoronary administration of BMSCs in the dilated 
cardiomyopathy population where no increased incidence of serious adverse effects 
compared to standard therapy over short and long-term follow-up. A similar trial to the 
BAMI consortium is needed to address whether the benefits we have shown in the 
REGENERATE-DCM trial translate to mortality benefit in this subset of patients.  
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Another limitation has been the debate over the use of surrogate endpoints in trials. It is 
now becoming crucial to develop an understanding of surrogate endpoints in clinical 
trials and their relevance to eventual outcome studies. The complexities of translational 
research mean that there is an unmet need for surrogate endpoints which can be used 
to reduce study size and duration and which have widely accepted meaning when it 
comes to hard clinical endpoints. Trials of innovative new therapies are expensive and, 
without robust surrogate endpoints that can reduce cost, they will remain out of reach of 
academia and perhaps represent too much risk for industry. Added to these difficulties 
are the ever-increasing regulatory issues which are clearly indicated but which need to 
be implemented in a way that allows the field to flourish rather than to flounder. 
Investment in infrastructure needs to accompany the creation of appropriate regulation. 
That said, the number of clinical trials continues to grow. Now, with the beginning of 
Phase III trials, a new page has been turned in this exciting story of discovery. 
 
 
 
 
 
 
 
 
133 
 
 
Reference List 
 
 
 
 
 
 
1 Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated 
cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. Am J 
Cardiol 1992; 69: 1458–66. 
2 Hertz MI, Aurora P, Christie JD, et al. Scientific Registry of the International Society for Heart 
and Lung Transplantation: introduction to the 2009 Annual Reports. J Heart Lung Transplant 
2009; 28: 989–92. 
3 Henry WL, Gardin JM, Ware JH. Echocardiographic measurements in normal subjects from 
infancy to old age. Circulation 1980; 62: 1054–61. 
4 Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position 
statement from the European Society Of Cardiology Working Group on Myocardial and 
Pericardial Diseases. Eur Heart J 2008; 29: 270–6. 
5 Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic 
cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. 
Circulation 1989; 80: 564–72. 
6 Rakar S, Sinagra G, Di Lenarda A, et al. Epidemiology of dilated cardiomyopathy. A prospective 
post-mortem study of 5252 necropsies. The Heart Muscle Disease Study Group. Eur Heart J 
1997; 18: 117–23. 
7 Baig MK, Goldman JH, Caforio AL, Coonar AS, Keeling PJ, McKenna WJ. Familial dilated 
cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may 
represent early disease. J Am Coll Cardiol 1998; 31: 195–201. 
8 Gavazzi A, Repetto A, Scelsi L, et al. Evidence-based diagnosis of familial non-X-linked dilated 
cardiomyopathy. Prevalence, inheritance and characteristics. Eur Heart J 2001; 22: 73–81. 
9 Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and 
phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999; 34: 181–
90. 
10 Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left 
ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common 
chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002; 
134 
 
 
23: 1867–76. 
11 Anand IS, Fisher LD, Chiang Y-T, et al. Changes in brain natriuretic peptide and norepinephrine 
over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). 
Circulation 2003; 107: 1278–83. 
12 Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones 
at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292–9. 
13 Canetti M, Akhter MW, Lerman A, et al. Evaluation of myocardial blood flow reserve in 
patients with chronic congestive heart failure due to idiopathic dilated cardiomyopathy. Am J 
Cardiol 2003; 92: 1246–9. 
14 Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment 
in idiopathic left ventricular dysfunction. Circulation 2002; 105: 186–93. 
15 Arnous S, Syrris P, Sen-Chowdhry S. Genetics of Dilated Cardiomyopathy: Risk of Conduction 
Defects and Sudden Cardiac Death. Cardiac Electrophysiology … 2010. 
16 Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum … 
2005. 
17 Tsubata S, Bowles KR, Vatta M, et al. Mutations in the human delta-sarcoglycan gene in 
familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106: 655–62. 
18 Barresi R, Di Blasi C, Negri T, et al. Disruption of heart sarcoglycan complex and severe 
cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet 2000; 37: 102–7. 
19 Arbustini E, Diegoli M, Morbini P, et al. Prevalence and characteristics of dystrophin defects in 
adult male patients with dilated cardiomyopathy. J Am Coll Cardiol 2000; 35: 1760–8. 
20 Taylor MRG, Slavov D, Ku L, et al. Prevalence of desmin mutations in dilated cardiomyopathy. 
Circulation 2007; 115: 1244–51. 
21 Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT. Actin mutations in dilated 
cardiomyopathy, a heritable form of heart failure. Science 1998; 280: 750–2. 
22 Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause 
of dilated cardiomyopathy. N Engl J Med 2000; 343: 1688–96. 
23 Kaski JP, Burch M, Elliott PM. Mutations in the cardiac Troponin C gene are a cause of 
idiopathic dilated cardiomyopathy in childhood. Cardiol Young 2007; 17: 675–7. 
24 Mogensen J, Murphy RT, Shaw T, et al. Severe disease expression of cardiac troponin C and T 
mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2004; 44: 
2033–40. 
25 Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C 
gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 
135 
 
 
341: 1715–24. 
26 Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with 
atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 2002; 39: 981–90. 
27 Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause 
autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999; 21: 285–8. 
28 Arbustini E, Diegoli M, Fasani R, et al. Mitochondrial DNA mutations and mitochondrial 
abnormalities in dilated cardiomyopathy. Am J Pathol 1998; 153: 1501–10. 
29 Kass S, MacRae C, Graber HL, et al. A gene defect that causes conduction system disease and 
dilated cardiomyopathy maps to chromosome 1p1-1q1. Nat Genet 1994; 7: 546–51. 
30 Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Linkage of familial dilated 
cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J 
Hum Genet 1997; 61: 909–17. 
31 Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L. Lamin A/C gene mutation 
associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 
2000; 101: 473–6. 
32 Caforio AL, Keeling PJ, Zachara E, et al. Evidence from family studies for autoimmunity in 
dilated cardiomyopathy. Lancet 1994; 344: 773–7. 
33 Caforio ALP, Mahon NG, Baig MK, et al. Prospective familial assessment in dilated 
cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic 
relatives. Circulation 2007; 115: 76–83. 
34 Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated 
cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility 
Project on Familial Dilated Cardiomyopathy. Eur. Heart J. 1999; 20: 93–102. 
35 Mahon NG, Murphy RT, MacRae CA, Caforio ALP, Elliott PM, McKenna WJ. Echocardiographic 
evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals 
preclinical disease. Ann Intern Med 2005; 143: 108–15. 
36 Mahon NG, Madden BP, Caforio ALP, et al. Immunohistologic evidence of myocardial disease in 
apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 
39: 455–62. 
37 Mahon NG, Sharma S, Elliott PM, et al. Abnormal cardiopulmonary exercise variables in 
asymptomatic relatives of patients with dilated cardiomyopathy who have left ventricular 
enlargement. Heart 2000; 83: 511–7. 
38 Daehmlow S, Erdmann J, Knueppel T, et al. Novel mutations in sarcomeric protein genes in 
dilated cardiomyopathy. Biochem Biophys Res Commun 2002; 298: 116–20. 
39 Villard E, Duboscq-Bidot L, Charron P, et al. Mutation screening in dilated cardiomyopathy: 
136 
 
 
prominent role of the beta myosin heavy chain gene. Eur Heart J 2005; 26: 794–803. 
40 Kärkkäinen S, Heliö T, Jääskeläinen P, et al. Two novel mutations in the beta-myosin heavy 
chain gene associated with dilated cardiomyopathy. Eur J Heart Fail 2004; 6: 861–8. 
41 Carniel E, Taylor MRG, Sinagra G, et al. Alpha-myosin heavy chain: a sarcomeric gene 
associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 2005; 
112: 54–9. 
42 Hanson EL, Jakobs PM, Keegan H, et al. Cardiac troponin T lysine 210 deletion in a family with 
dilated cardiomyopathy. J Card Fail 2002; 8: 28–32. 
43 Murphy RT, Mogensen J, Shaw A, Kubo T, Hughes S, McKenna WJ. Novel mutation in cardiac 
troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 2004; 363: 371–2. 
44 Carballo S, Robinson P, Otway R, et al. Identification and functional characterization of cardiac 
troponin I as a novel disease gene in autosomal dominant dilated cardiomyopathy. Circ Res 
2009; 105: 375–82. 
45 Hershberger RE, Norton N, Morales A, Li D, Siegfried JD, Gonzalez-Quintana J. Coding sequence 
rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with 
familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet 2010; 3: 155–61. 
46 Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament 
titin, cause familial dilated cardiomyopathy. Nat Genet 2002; 30: 201–4. 
47 Knöll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery 
involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 
2002; 111: 943–55. 
48 Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic 
cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004; 44: 2192–201. 
49 Olson TM, Illenberger S, Kishimoto NY, Huttelmaier S, Keating MT, Jockusch BM. Metavinculin 
mutations alter actin interaction in dilated cardiomyopathy. Circulation 2002; 105: 431–7. 
50 Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP in patients with dilated 
cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003; 42: 2014–27. 
51 Mohapatra B, Jimenez S, Lin J-H, et al. Mutations in the muscle LIM protein and alpha-actinin-2 
genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 2003; 80: 
207–15. 
52 Arola AM, Sanchez X, Murphy RT, et al. Mutations in PDLIM3 and MYOZ1 encoding myocyte Z 
line proteins are infrequently found in idiopathic dilated cardiomyopathy. Mol Genet Metab 
2007; 90: 435–40. 
53 Duboscq-Bidot L, Xu P, Charron P, et al. Mutations in the Z-band protein myopalladin gene and 
idiopathic dilated cardiomyopathy. Cardiovasc Res 2008; 77: 118–25. 
137 
 
 
54 Arimura T, Hayashi T, Matsumoto Y, et al. Structural analysis of four and half LIM protein-2 in 
dilated cardiomyopathy. Biochem Biophys Res Commun 2007; 357: 162–7. 
55 Hassel D, Dahme T, Erdmann J, et al. Nexilin mutations destabilize cardiac Z-disks and lead to 
dilated cardiomyopathy. Nat Med 2009; 15: 1281–8. 
56 Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated 
cardiomyopathy. Circulation 1999; 100: 461–4. 
57 Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic 
evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. 
Circulation 1993; 87: 1854–65. 
58 Inagaki N, Hayashi T, Arimura T, et al. Alpha B-crystallin mutation in dilated cardiomyopathy. 
Biochem Biophys Res Commun 2006; 342: 379–86. 
59 Jakobs PM, Hanson EL, Crispell KA, et al. Novel lamin A/C mutations in two families with 
dilated cardiomyopathy and conduction system disease. J Card Fail 2001; 7: 249–56. 
60 Vytopil M, Benedetti S, Ricci E, et al. Mutation analysis of the lamin A/C gene (LMNA) among 
patients with different cardiomuscular phenotypes. J Med Genet 2003; 40: e132. 
61 Taylor MRG, Fain PR, Sinagra G, et al. Natural history of dilated cardiomyopathy due to lamin 
A/C gene mutations. J Am Coll Cardiol 2003; 41: 771–80. 
62 Sylvius N, Bilinska ZT, Veinot JP, et al. In vivo and in vitro examination of the functional 
significances of novel lamin gene mutations in heart failure patients. J Med Genet 2005; 42: 
639–47. 
63 Sébillon P, Bouchier C, Bidot LD, et al. Expanding the phenotype of LMNA mutations in dilated 
cardiomyopathy and functional consequences of these mutations. J Med Genet 2003; 40: 560–
7. 
64 Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am 
Coll Cardiol 2005; 45: 969–81. 
65 Taylor MRG, Slavov D, Gajewski A, et al. Thymopoietin (lamina-associated polypeptide 2) gene 
mutation associated with dilated cardiomyopathy. Hum Mutat 2005; 26: 566–74. 
66 Bione S, Small K, Aksmanovic VM, et al. Identification of new mutations in the Emery-Dreifuss 
muscular dystrophy gene and evidence for genetic heterogeneity of the disease. Hum Mol 
Genet 1995; 4: 1859–63. 
67 Bienengraeber M, Olson TM, Selivanov VA, et al. ABCC9 mutations identified in human dilated 
cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet 2004; 36: 382–7. 
68 Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts 
desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly 
hair and keratoderma. Hum Mol Genet 2000; 9: 2761–6. 
138 
 
 
69 Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a 
mutation in phospholamban. Science 2003; 299: 1410–3. 
70 Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated 
cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003; 
111: 869–76. 
71 Haghighi K, Kolokathis F, Gramolini AO, et al. A mutation in the human phospholamban gene, 
deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA 2006; 
103: 1388–93. 
72 D'Adamo P, Fassone L, Gedeon A, et al. The X-linked gene G4.5 is responsible for different 
infantile dilated cardiomyopathies. Am J Hum Genet 1997; 61: 862–7. 
73 Zhang L, Hu A, Yuan H, et al. A missense mutation in the CHRM2 gene is associated with 
familial dilated cardiomyopathy. Circ Res 2008; 102: 1426–32. 
74 Schönberger J, Wang L, Shin JT, et al. Mutation in the transcriptional coactivator EYA4 causes 
dilated cardiomyopathy and sensorineural hearing loss. Nat Genet 2005; 37: 418–22. 
75 Taylor MRG, Ku L, Slavov D, et al. Danon disease presenting with dilated cardiomyopathy and a 
complex phenotype. J Hum Genet 2007; 52: 830–5. 
76 Knöll R, Postel R, Wang J, et al. Laminin-alpha4 and integrin-linked kinase mutations cause 
human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. 
Circulation 2007; 116: 515–25. 
77 Li D, Parks SB, Kushner JD, et al. Mutations of presenilin genes in dilated cardiomyopathy and 
heart failure. Am J Hum Genet 2006; 79: 1030–9. 
78 Moulik M, Vatta M, Witt SH, et al. ANKRD1, the gene encoding cardiac ankyrin repeat protein, 
is a novel dilated cardiomyopathy gene. J Am Coll Cardiol 2009; 54: 325–33. 
79 Brauch KM, Karst ML, Herron KJ, et al. Mutations in ribonucleic acid binding protein gene cause 
familial dilated cardiomyopathy. J Am Coll Cardiol 2009; 54: 930–41. 
80 Montastruc G, Favreliere S, Sommet A, et al. Drugs and dilated cardiomyopathies: A 
case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol 2010; 69: 
287–94. 
81 Pantazis AA, Elliott PM. Left ventricular noncompaction. Curr Opin Cardiol 2009; 24: 209–13. 
82 Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of 
Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in 
collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the 
European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008; 29: 2388–442. 
83 Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden 
139 
 
 
death in patients with lamin A/C gene mutations. N Engl J Med 2006; 354: 209–10. 
84 Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated 
cardiolaminopathies. J Am Coll Cardiol 2008; 52: 1250–60. 
85 Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 
299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden 
death? J Mol Med 2005; 83: 79–83. 
86 Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. The Registry of the 
International Society for Heart and Lung Transplantation: twenty-first official adult heart 
transplant report--2004. J Heart Lung Transplant 2004; 23: 796–803. 
87 Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting 
heart transplantation. N Engl J Med 2007; 357: 885–96. 
88 Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow 
left ventricular assist device. N Engl J Med 2009; 361: 2241–51. 
89 McAlister FA, Stewart S, Ferrua S, McMurray JJJV. Multidisciplinary strategies for the 
management of heart failure patients at high risk for admission: a systematic review of 
randomized trials. J Am Coll Cardiol 2004; 44: 810–9. 
90 Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total 
mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL 
Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. 
JAMA 2000; 283: 1295–302. 
91 Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in 
patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N 
Engl J Med 1999; 341: 709–17. 
92 Lader E, Egan D, Hunsberger S, Garg R, Czajkowski S, McSherry F. The effect of digoxin on the 
quality of life in patients with heart failure. J Card Fail 2003; 9: 4–12. 
93 Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting 
the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J 
Cardiol 2002; 82: 149–58. 
94 McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in 
heart failure. N Engl J Med 2014; 371: 993–1004. 
95 Lovell MJ, Mathur A. The role of stem cells for treatment of cardiovascular disease. Cell Prolif 
2004; 37: 67–87. 
96 Poulsom R, Alison MR, Forbes SJ, Wright NA. Adult stem cell plasticity. J Pathol 2002; 197: 441–
56. 
97 Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, 
140 
 
 
improving function and survival. Proc Natl Acad Sci USA 2001; 98: 10344–9. 
98 Norol F, Merlet P, Isnard R, et al. Influence of mobilized stem cells on myocardial infarct repair 
in a nonhuman primate model. Blood 2003; 102: 4361–8. 
99 Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells 
differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 
93–8. 
100 Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves 
cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005; 112: 1128–35. 
101 Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and 
progenitor cells. Blood 1997; 90: 5002–12. 
102 Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell 
antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013–21. 
103 Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded 
endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634–7. 
104 Kamihata H, Matsubara H, Nishiue T, et al. Improvement of collateral perfusion and regional 
function by implantation of peripheral blood mononuclear cells into ischemic hibernating 
myocardium. Arterioscler Thromb Vasc Biol 2002; 22: 1804–10. 
105 Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration 
Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009–17. 
106 Stamm C, Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for 
myocardial regeneration. Lancet 2003; 361: 45–6. 
107 Chen S-L, Fang W-W, Ye F, et al. Effect on left ventricular function of intracoronary 
transplantation of autologous bone marrow mesenchymal stem cell in patients with acute 
myocardial infarction. Am J Cardiol 2004; 94: 92–5. 
108 Fernández-Avilés F, San Román JA, García-Frade J, et al. Experimental and clinical regenerative 
capability of human bone marrow cells after myocardial infarction. Circ Res 2004; 95: 742–8. 
109 Schächinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and 
regeneration enhancement in acute myocardial infarction: final one-year results of the 
TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690–9. 
110 Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after 
myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141–8. 
111 Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved 
performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929–33. 
112 Menasché P, Hagège A, Scorsin M, et al. [Autologous skeletal myoblast transplantation for 
141 
 
 
cardiac insufficiency. First clinical case]. Arch Mal Coeur Vaiss 2001; 94: 180–2. 
113 Hagège AA, Marolleau J-P, Vilquin J-T, et al. Skeletal myoblast transplantation in ischemic heart 
failure: long-term follow-up of the first phase I cohort of patients. Circulation 2006; 114: I108–
13. 
114 Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic 
Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast 
transplantation. Circulation 2008; 117: 1189–200. 
115 Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after 
myocardial infarction. N Engl J Med 2001; 344: 1750–7. 
116 Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support 
myocardial regeneration. Cell 2003; 114: 763–76. 
117 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult 
fibroblast cultures by defined factors. Cell 2006; 126: 663–76. 
118 Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human 
fibroblasts by defined factors. Cell 2007; 131: 861–72. 
119 Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem 
cells from human keratinocytes. Nat Biotechnol 2008; 26: 1276–84. 
120 Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem 
cells. Nature 2007; 448: 313–7. 
121 Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates 
integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 
2004; 432: 466–72. 
122 Smart N, Risebro CA, Melville AAD, et al. Thymosin beta4 induces adult epicardial progenitor 
mobilization and neovascularization. Nature 2007; 445: 177–82. 
123 Bock-Marquette I, Shrivastava S, Pipes GCT, et al. Thymosin beta4 mediated PKC activation is 
essential to initiate the embryonic coronary developmental program and epicardial progenitor 
cell activation in adult mice in vivo. J Mol Cell Cardiol 2009; 46: 728–38. 
124 Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult 
heart after injury. Nature 2011; 474: 640–4. 
125 Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. 
Nature 2001; 410: 701–5. 
126 Yoon Y-S, Lee N, Scadova H. Myocardial regeneration with bone-marrow-derived stem cells. 
Biol Cell 2005; 97: 253–63. 
127 Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone 
142 
 
 
marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008; 
29: 1807–18. 
128 Lipinski MJ, Biondi-Zoccai GGL, Abbate A, et al. Impact of intracoronary cell therapy on left 
ventricular function in the setting of acute myocardial infarction: a collaborative systematic 
review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007; 50: 1761–7. 
129 Abdel-Latif A, Bolli R, Tleyjeh IM. Adult bone marrow-derived cells for cardiac repair: A 
systematic review and meta-analysis. Arch Intern Med 2007; 167: 989–97. 
130 Reffelmann T, Könemann S, Kloner RA. Promise of blood- and bone marrow-derived stem cell 
transplantation for functional cardiac repair: putting it in perspective with existing therapy. J 
Am Coll Cardiol 2009; 53: 305–8. 
131 Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without 
abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–66. 
132 Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with 
coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–903. 
133 Yousef M, Schannwell CM, Köstering M, Zeus T, Brehm M, Strauer BE. The BALANCE Study: 
clinical benefit and long-term outcome after intracoronary autologous bone marrow cell 
transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009; 53: 2262–
9. 
134 Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, 
and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003; 42: 736–42. 
135 Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection 
fraction: a 5 year prospective population-based study. Eur Heart J 2008; 29: 339–47. 
136 Sharif F, Bartunek J, Vanderheyden M. Adult stem cells in the treatment of acute myocardial 
infarction. Catheter Cardiovasc Interv 2011; 77: 72–83. 
137 Li T-S, Mikamo A, Takahashi M, et al. Comparison of cell therapy and cytokine therapy for 
functional repair in ischemic and nonischemic heart failure. Cell Transplant 2007; 16: 365–74. 
138 Ghodsizad A, Ruhparwar A, Marktanner R, et al. Autologous transplantation of CD133+ BM-
derived stem cells as a therapeutic option for dilatative cardiomyopathy. Cytotherapy 2006; 8: 
308–10. 
139 Argüero R, Careaga-Reyna G, Castaño-Guerra R, Garrido-Garduño MH, Magaña-Serrano JA, de 
Jesús Nambo-Lucio M. Cellular autotransplantation for ischemic and idiopathic dilated 
cardiomyopathy. Preliminary report. Arch Med Res 2006; 37: 1010–4. 
140 Martino HF, Oliveira PS, Assunção E, et al. [Cell therapy in dilated cardiomyopathy]. Arq Bras 
Cardiol 2006; 86: 390–2. 
141 Zeinaloo A, Zanjani KS, Bagheri MM, Mohyeddin-Bonab M, Monajemzadeh M, Arjmandnia MH. 
143 
 
 
Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient 
with dilated cardiomyopathy. Pediatr Transplant 2011; 15: E183–6. 
142 Seth S, Narang R, Bhargava B, et al. Percutaneous intracoronary cellular cardiomyoplasty for 
nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD 
(Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J Am Coll Cardiol 2006; 48: 
2350–1. 
143 Rupp S, Bauer J, Tonn T, et al. Intracoronary administration of autologous bone marrow-
derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy. Pediatr 
Transplant 2009; 13: 620–3. 
144 Fischer-Rasokat U, Assmus B, Seeger FH, et al. A pilot trial to assess potential effects of 
selective intracoronary bone marrow-derived progenitor cell infusion in patients with 
nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor 
cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated 
cardiomyopathy. Circ Heart Fail 2009; 2: 417–23. 
145 Vrtovec B, Poglajen G, Sever M, et al. Effects of intracoronary stem cell transplantation in 
patients with dilated cardiomyopathy. J Card Fail 2011; 17: 272–81. 
146 Meluzín J, Mayer J, Groch L, et al. Autologous transplantation of mononuclear bone marrow 
cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on 
myocardial function. Am Heart J 2006; 152: 975.e9–15. 
147 Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in 
patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled 
trial. Lancet 2006; 367: 113–21. 
148 Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells 
in acute myocardial infarction. N Engl J Med 2006; 355: 1199–209. 
149 Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in 
acute myocardial infarction. N Engl J Med 2006; 355: 1210–21. 
150 Ge J, Li Y, Qian J, et al. Efficacy of emergent transcatheter transplantation of stem cells for 
treatment of acute myocardial infarction (TCT-STAMI). Heart 2006; 92: 1764–7. 
151 de Lezo JS, Herrera C, Pan M, et al. Regenerative therapy in patients with a revascularized 
acute anterior myocardial infarction and depressed ventricular function. Rev Esp Cardiol (Engl 
Ed) 2007; 60: 357–65. 
152 Lipiec P, Krzemińska-Pakuła M, Plewka M, et al. Impact of intracoronary injection of 
mononuclear bone marrow cells in acute myocardial infarction on left ventricular perfusion 
and function: a 6-month follow-up gated 99mTc-MIBI single-photon emission computed 
tomography study. Eur J Nucl Med Mol Imaging 2009; 36: 587–93. 
153 Huikuri HV, Kervinen K, Niemelä M, et al. Effects of intracoronary injection of mononuclear 
bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after 
144 
 
 
thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008; 29: 2723–32. 
154 Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous 
intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 
106: 1913–8. 
155 Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD133-
positive enriched bone marrow progenitor cells promotes cardiac recovery after recent 
myocardial infarction: feasibility and safety. Circulation 2005; 112: I178–83. 
156 Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from 
bone marrow or peripheral blood compared with standard therapy in patients after acute 
myocardial infarction treated by primary percutaneous coronary intervention: results of the 
randomized controlled HEBE trial. Eur Heart J 2011; 32: 1736–47. 
157 Kuethe F, Richartz BM, Sayer HG, et al. Lack of regeneration of myocardium by autologous 
intracoronary mononuclear bone marrow cell transplantation in humans with large anterior 
myocardial infarctions. Int J Cardiol 2004; 97: 123–7. 
158 Penicka M, Horak J, Kobylka P, et al. Intracoronary injection of autologous bone marrow-
derived mononuclear cells in patients with large anterior acute myocardial infarction: a 
prematurely terminated randomized study. J Am Coll Cardiol 2007; 49: 2373–4. 
159 Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 
1996; 88: 761–77. 
160 Anderlini P, Donato M, Chan KW, et al. Allogeneic blood progenitor cell collection in normal 
donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. 
Transfusion 1999; 39: 555–60. 
161 Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood 
stem cells. J Hematother 1992; 1: 329–41. 
162 Bodine DM, Seidel NE, Gale MS, Nienhuis AW, Orlic D. Efficient retrovirus transduction of 
mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment 
with granulocyte colony-stimulating factor and stem cell factor. Blood 1994; 84: 1482–91. 
163 Kurdi M, Booz GW. G-CSF-based stem cell therapy for the heart-unresolved issues part A: 
paracrine actions, mobilization, and delivery. Congest Heart Fail 2007; 13: 221–7. 
164 Harada M, Qin Y, Minamino T, Toko H. G-CSF Prevents Cardiac Remodeling after Myocardial 
Infarction by Activating Jak/STAT in Cardiomyocytes (Vascular Regeneration (M), The 69th 
Annual …. … journal: official journal … 2005. 
165 Joseph J, Rimawi A, Mehta P, et al. Safety and effectiveness of granulocyte-colony stimulating 
factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. 
Am J Cardiol 2006; 97: 681–4. 
166 Hüttmann A, Dührsen U, Stypmann J, et al. Granulocyte colony-stimulating factor-induced 
145 
 
 
blood stem cell mobilisation in patients with chronic heart failure--Feasibility, safety and 
effects on exercise tolerance and cardiac function. Basic Res Cardiol 2006; 101: 78–86. 
167 Kuethe F, Figulla HR, Herzau M, et al. Treatment with granulocyte colony-stimulating factor for 
mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 
2005; 150: 115. 
168 Ince H, Petzsch M, Kleine HD, et al. Prevention of left ventricular remodeling with granulocyte 
colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-
Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction 
by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 2005; 112: I73–80. 
169 Ripa RS, Jørgensen E, Wang Y, et al. Stem cell mobilization induced by subcutaneous 
granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation 
myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in 
myocardial infarction (STEMMI) trial. Circulation 2006; 113: 1983–92. 
170 Abdel-Latif A, Bolli R, Zuba-Surma EK, Tleyjeh IM, Hornung CA, Dawn B. Granulocyte colony-
stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic 
review and meta-analysis of randomized controlled trials. Am Heart J 2008; 156: 216–9. 
171 Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in 
healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 2506–14. 
172 Kang H-J, Kim H-S, Zhang S-Y, et al. Effects of intracoronary infusion of peripheral blood stem-
cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function 
and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised 
clinical trial. Lancet 2004; 363: 751–6. 
173 Engelmann MG, Theiss HD, Hennig-Theiss C, et al. Autologous bone marrow stem cell 
mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment 
elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-
STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) 
trial. J Am Coll Cardiol 2006; 48: 1712–21. 
174 Jørgensen E, Ripa RS, Helqvist S, et al. In-stent neo-intimal hyperplasia after stem cell 
mobilization by granulocyte-colony stimulating factor Preliminary intracoronary ultrasound 
results from a double-blind randomized placebo-controlled study of patients treated with 
percutaneous coronary intervention for ST-elevation myocardial infarction (STEMMI Trial). Int J 
Cardiol 2006; 111: 174–7. 
175 Leone AM, Giannico MB, Bruno I, et al. Safety and efficacy of G-CSF in patients with ischemic 
heart failure: the CORNER (Cell Option For Recovery in the Non-Eligible Patients for 
Revascularization) study. Int J Cardiol 2011; 150: 75–8. 
176 Francis DP, Shamim W, Davies LC, et al. Cardiopulmonary exercise testing for prognosis in 
chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and 
peak VO(2). Eur Heart J 2000; 21: 154–61. 
146 
 
 
177 Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide 
dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10. 
178 Milani RV, Lavie CJ, Mehra MR, Ventura HO. Understanding the basics of cardiopulmonary 
exercise testing. Mayo Clin Proc 2006; 81: 1603–11. 
179 Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human 
CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952–
8. 
180 Tomita S, Ishida M, Nakatani T, et al. Bone marrow is a source of regenerated cardiomyocytes 
in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances 
migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron 
microscopy. J Heart Lung Transplant 2004; 23: 577–84. 
181 Hamamoto M, Tomita S, Nakatani T, et al. Granulocyte-colony stimulating factor directly 
enhances proliferation of human troponin I-positive cells derived from idiopathic dilated 
cardiomyopathy through specific receptors. J Heart Lung Transplant 2004; 23: 1430–7. 
182 Wang X, Hu Q, Mansoor A, et al. Bioenergetic and functional consequences of stem cell-based 
VEGF delivery in pressure-overloaded swine hearts. Am J Physiol Heart Circ Physiol 2006; 290: 
H1393–405. 
183 Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a 
systematic review and meta-analysis. Arch Intern Med 2007; 167: 989–97. 
184 Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate 
into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664–8. 
185 Mathur A, Martin JF. Stem cells and repair of the heart. Lancet 2004; 364: 183–92. 
186 Mozid AM, Jones D, Arnous S, et al. The effects of age, disease state, and granulocyte colony-
stimulating factor on progenitor cell count and function in patients undergoing cell therapy for 
cardiac disease. Stem Cells Dev 2013; 22: 216–23. 
187 Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating 
endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. 
Circ Res 2001; 89: E1–7. 
188 Hocking DC, Phillips PG, Ferro TJ, Johnson A. Mechanisms of pulmonary edema induced by 
tumor necrosis factor-alpha. Circ Res 1990; 67: 68–77. 
189 Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and 
mortality in patients with unstable coronary artery disease: effects of an early invasive or 
noninvasive strategy. JAMA 2001; 286: 2107–13. 
190 Jernberg T, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide in relation to 
inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary 
artery disease. J Am Coll Cardiol 2003; 42: 1909–16. 
147 
 
 
191 James SK, Lindahl B, Timmer JR, et al. Usefulness of biomarkers for predicting long-term 
mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a 
GUSTO IV substudy). Am J Cardiol 2006; 97: 167–72. 
192 Kavsak PA, Ko DT, Newman AM, et al. Risk stratification for heart failure and death in an acute 
coronary syndrome population using inflammatory cytokines and N-terminal pro-brain 
natriuretic peptide. Clin Chem 2007; 53: 2112–8. 
193 Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of 
heart failure and mortality in survivors of acute myocardial infarction predictive role of C-
reactive protein. J Am Coll Cardiol 2006; 47: 962–8. 
194 Kavsak PA, MacRae AR, Newman AM, et al. Elevated C-reactive protein in acute coronary 
syndrome presentation is an independent predictor of long-term mortality and heart failure. 
Clin Biochem 2007; 40: 326–9. 
195 Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent 
adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth 
University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010; 105: 1371–1. 
196 Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of 
inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am 
Coll Cardiol 2001; 37: 412–7. 
197 Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting 
enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34: 2061–
7. 
198 McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in 
emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational 
Study. Circulation 2002; 106: 416–22. 
199 Moe GW. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006; 21: 208–14. 
200 Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting 
diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595–
601. 
201 Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic 
peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–7. 
202 Maisel AS, McCord J, Nowak RM, et al. Bedside B-Type natriuretic peptide in the emergency 
diagnosis of heart failure with reduced or preserved ejection fraction. Results from the 
Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41: 2010–7. 
203 Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of 
cardiovascular events and death. N Engl J Med 2004; 350: 655–63. 
204 Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical 
148 
 
 
marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic 
left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur 
Heart J 1999; 20: 1799–807. 
205 Hülsmann M, Berger R, Sturm B, et al. Prediction of outcome by neurohumoral activation, the 
six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an 
outpatient cohort with congestive heart failure. Eur Heart J 2002; 23: 886–91. 
206 Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to 
improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 
49: 1733–9. 
207 Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of 
heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) 
concentrations. Lancet 2000; 355: 1126–30. 
208 Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation 
and management of acute dyspnea. N Engl J Med 2004; 350: 647–54. 
209 Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in 
patients with chronic heart failure. Circulation 2002; 105: 2392–7. 
210 Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic 
peptide. A new gold standard in predicting mortality in patients with advanced heart failure. 
Eur Heart J 2003; 24: 1735–43. 
211 Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac 
natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic 
peptide concentration in patients with chronic symptomatic left ventricular dysfunction. 
Circulation 1997; 96: 509–16. 
212 Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 
2011; 117: 3720–32. 
213 Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–52. 
214 Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106–13. 
215 Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human 
interleukin-2. Nature 1983; 302: 305–10. 
216 Pericle F, Liu JH, Diaz JI, et al. Interleukin-2 prevention of apoptosis in human neutrophils. Eur J 
Immunol 1994; 24: 440–4. 
217 Nakanishi K, Hirose S, Yoshimoto T, et al. Role and regulation of interleukin (IL)-2 receptor 
alpha and beta chains in IL-2-driven B-cell growth. Proc Natl Acad Sci USA 1992; 89: 3551–5. 
218 Rubin JT. Interleukin-2: its biology and clinical application in patients with cancer. Cancer Invest 
1993; 11: 460–72. 
149 
 
 
219 Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory 
effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, 
interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86: 3803–7. 
220 Boey H, Rosenbaum R, Castracane J, Borish L. Interleukin-4 is a neutrophil activator. J Allergy 
Clin Immunol 1989; 83: 978–84. 
221 Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated 
levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992; 90: 1479–
85. 
222 Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-
4. Cancer Res 1992; 52: 275–9. 
223 Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors 
on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-
4. J Clin Invest 1993; 91: 88–93. 
224 Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–78. 
225 Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 
265: 621–36. 
226 Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 
1992; 258: 593–7. 
227 Wong GG, Witek-Giannotti JS, Temple PA, et al. Stimulation of murine hemopoietic colony 
formation by human IL-6. J Immunol 1988; 140: 3040–4. 
228 Bhardwaj N, Santhanam U, Lau LL, et al. IL-6/IFN-beta 2 in synovial effusions of patients with 
rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of 
cellular sources. J Immunol 1989; 143: 2153–9. 
229 Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the 
risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 
1767–72. 
230 Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a 
human interleukin-8 receptor. Science 1991; 253: 1278–80. 
231 Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel 
proinflammatory supergene ‘intercrine’ cytokine family. Annu Rev Immunol 1991; 9: 617–48. 
232 Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MCAF: novel leukocyte recruitment 
and activating cytokines. Chem Immunol 1992; 51: 236–65. 
233 Windsor WT, Syto R, Tsarbopoulos A, et al. Disulfide bond assignments and secondary 
structure analysis of human and murine interleukin 10. Biochemistry 1993; 32: 8807–15. 
150 
 
 
234 Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev 
Immunol 1993; 11: 165–90. 
235 Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase 
and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 
2304–10. 
236 Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM. Interleukin-10 inhibits interleukin-8 
production in human neutrophils. Blood 1994; 83: 2678–83. 
237 Wang B, Zhuang L, Fujisawa H, et al. Enhanced epidermal Langerhans cell migration in IL-10 
knockout mice. J Immunol 1999; 162: 277–83. 
238 Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the anti-
inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci 
2003; 105: 45–50. 
239 de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits 
cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by 
monocytes. J Exp Med 1991; 174: 1209–20. 
240 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 
18: 4–25. 
241 Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor 
(vascular endothelial growth factor) gene is expressed differentially in normal tissues, 
macrophages, and tumors. Mol Biol Cell 1992; 3: 211–20. 
242 Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial 
growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 
1029–39. 
243 Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on 
hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27: 838–44. 
244 Seko Y, Imai Y, Suzuki S, et al. Serum levels of vascular endothelial growth factor in patients 
with acute myocardial infarction undergoing reperfusion therapy. Clin Sci 1997; 92: 453–4. 
245 Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y. Vascular endothelial growth 
factor in acute Kawasaki disease. Am J Cardiol 1999; 83: 337–9. 
246 Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 
2002; 136: 54–71. 
247 Weck KE, Dal Canto AJ, Gould JD, et al. Murine gamma-herpesvirus 68 causes severe large-
vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-
induced vascular disease. Nat Med 1997; 3: 1346–53. 
248 Rea IM, McNerlan SE, Alexander HD. CD69, CD25, and HLA-DR activation antigen expression on 
151 
 
 
CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging. 
Exp Gerontol 1999; 34: 79–93. 
249 Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent 
angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250–3. 
250 Schultz G, Rotatori DS, Clark W. EGF and TGF-alpha in wound healing and repair. J Cell Biochem 
1991; 45: 346–52. 
251 Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its 
multiple actions. J Biol Chem 1991; 266: 7313–6. 
252 Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and 
fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355–7. 
253 Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease 
progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467–72. 
254 Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe 
congestive cardiac failure. Br Heart J 1993; 70: 141–3. 
255 Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis 
factor in severe chronic heart failure. N Engl J Med 1990; 323: 236–41. 
256 Başaran Y, Başaran MM, Babacan KF, et al. Serum tumor necrosis factor levels in acute 
myocardial infarction and unstable angina pectoris. Angiology 1993; 44: 332–7. 
257 Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis 
factor-alpha and increased risk of recurrent coronary events after myocardial infarction. 
Circulation 2000; 101: 2149–53. 
258 Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart 
failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987; 59: 
634–8. 
259 Parameshwar J, Keegan J, Sparrow J, Sutton GC, Poole-Wilson PA. Predictors of prognosis in 
severe chronic heart failure. Am Heart J 1992; 123: 421–6. 
260 Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild 
to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989; 14: 564–70–
discussion571–2. 
261 Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental 
observations and clinical implications. Circulation 1990; 81: 1161–72. 
262 Weber KT, Kinasewitz GT, Janicki JS, Fishman AP. Oxygen utilization and ventilation during 
exercise in patients with chronic cardiac failure. Circulation 1982; 65: 1213–23. 
263 Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, 
152 
 
 
cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of 
prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI5–
16. 
264 Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing 
using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated 
cardiomyopathy. J Am Coll Cardiol 1996; 27: 345–52. 
265 Bensimhon DR, Leifer ES, Ellis SJ, et al. Reproducibility of peak oxygen uptake and other 
cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart 
Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). Am J Cardiol 2008; 
102: 712–7. 
266 Balady GJ, Arena R, Sietsema K, et al. Clinician's Guide to cardiopulmonary exercise testing in 
adults: a scientific statement from the American Heart Association. Circulation. 2010; 122: 191–
225. 
267 Agostoni P, Bianchi M, Moraschi A, et al. Work-rate affects cardiopulmonary exercise test 
results in heart failure. Eur J Heart Fail 2005; 7: 498–504. 
268 Myers J, Goldsmith RL, Keteyian SJ, et al. The ventilatory anaerobic threshold in heart failure: a 
multicenter evaluation of reliability. J Card Fail 2010; 16: 76–83. 
269 Agostoni P, Corrà U, Cattadori G, et al. Prognostic value of indeterminable anaerobic threshold 
in heart failure. Circ Heart Fail 2013; 6: 977–87. 
270 Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: 
summary article: a report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). 
Circulation. 2002; 106: 1883–92. 
271 Arena R, Myers J, Williams MA, et al. Assessment of functional capacity in clinical and research 
settings: a scientific statement from the American Heart Association Committee on Exercise, 
Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on 
Cardiovascular Nursing. Circulation 2007; 116: 329–43. 
272 Valeur N, Clemmensen P, Saunamäki K, Grande P, DANAMI-2 investigators. The prognostic 
value of pre-discharge exercise testing after myocardial infarction treated with either primary 
PCI or fibrinolysis: a DANAMI-2 sub-study. Eur Heart J 2005; 26: 119–27. 
273 Seth S, Bhargava B, Narang R, et al. The ABCD (Autologous Bone Marrow Cells in Dilated 
Cardiomyopathy) trial a long-term follow-up study. J Am Coll Cardiol 2010; 55: 1643–4. 
274 Vrtovec B, Poglajen G, Lezaic L, et al. Effects of intracoronary CD34+ stem cell transplantation 
in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 2013; 112: 165–73. 
275 Iwanaga K, Takano H, Ohtsuka M, et al. Effects of G-CSF on cardiac remodeling after acute 
myocardial infarction in swine. Biochem Biophys Res Commun 2004; 325: 1353–9. 
153 
 
 
276 Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health 
Organization/International Society and Federation of Cardiology Task Force on the Definition 
and Classification of cardiomyopathies. Circulation. 1996; 93: 841–2. 
277 Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in 
left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA 
Cooperative Studies Group. Circulation 1993; 87: VI17–23. 
278 Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a 
consensus paper from an international forum on cardiac remodeling. Behalf of an International 
Forum on Cardiac Remodeling., 2000: 569–82. 
279 Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic 
dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 
Lancet 1993; 342: 1441–6. 
280 Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with 
mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94: 
2800–6. 
281 A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study 
(CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90: 1765–73. 
282 Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting 
enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in 
patients with heart failure. SOLVD Investigators. Circulation 1992; 86: 431–8. 
283 Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac 
structure and function in patients with left ventricular dysfunction. Results of the SOLVD 
echocardiography substudy. Circulation 1995; 91: 2573–81. 
284 Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with 
carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-
New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29: 1060–6. 
285 Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic 
effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 
1997; 96: 2197–205. 
286 Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) 
testing. Eur Heart J 2003; 24: 1710–8. 
287 Valli N, Georges A, Corcuff JB, Barat JL, Bordenave L. Assessment of brain natriuretic peptide in 
patients with suspected heart failure: comparison with radionuclide ventriculography data. Clin 
Chim Acta 2001; 306: 19–26. 
288 Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain 
natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll 
Cardiol 2001; 38: 1934–41. 
154 
 
 
289 Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in 
patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for 
ventricular remodeling. Mayo Clin Proc 2001; 76: 1111–9. 
290 O'Neill JO, Bott-Silverman CE, McRae AT, et al. B-type natriuretic peptide levels are not a 
surrogate marker for invasive hemodynamics during management of patients with severe 
heart failure. Am Heart J 2005; 149: 363–9. 
291 Nishii M, Inomata T, Takehana H, et al. Prognostic utility of B-type natriuretic peptide 
assessment in stable low-risk outpatients with nonischemic cardiomyopathy after 
decompensated heart failure. J Am Coll Cardiol 2008; 51: 2329–35. 
292 Bartunek J, Dimmeler S, Drexler H, et al. The consensus of the task force of the European 
Society of Cardiology concerning the clinical investigation of the use of autologous adult stem 
cells for repair of the heart. Eur Heart J 2006; 27: 1338–40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
 
 
 
Appendix 
Publications 
The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-
DCM) trial: study design. 
Arnous S, Mozid A, Mathur A. 
Regenerative Medicine. 2011 Jul;6(4):525-33. 
 
Bone marrow mononuclear cells and acute myocardial infarction 
Arnous S, Mozid A, Martin J, Mathur A. 
Stem Cell Research and Therapy. 2012 Jan 17;3(1):2. 
 
Stem Cell Therapy for Heart Diseases 
Mozid AM, Arnous S, Sammut EC, Mathur A 
British Medical Bulletin, 2011;98:143-59 
 
Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell 
therapy in advanced heart failure: the REGENERATE-IHD pilot study.                                                                               
Mozid A, Yeo C, Arnous S, Ako E, Saunders N, Locca D, Brookman P, Archbold RA, Rothman 
M, Mills P, Agrawal S, Martin J, Mathur A.                                                                                                                           
Regen Med. 2014 May;9(3):269-78 
 
The Effects of age, disease state and granulocyte-colony stimulating factor on progenitor 
cell count and function in patients undergoing cell therapy for cardiac disease.                                                                                        
Mozid A, Jones D, Arnous S, Saunders N, Wragg A, Martin J, Agrawal S, Mathur A. 
Stem Cells and Development. 2013 Jan 15;22(2):216-23 
 
The long-term survival and the risks and benefits of implantable cardioverter 
defibrillators in patients with hypertrophic cardiomyopathy. 
O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, Al-Shaikh S, 
Rahman SM, Arnous S, Jones S, McKenna W, Elliott P. 
Heart. 2012 Jan;98(2):116-25. 
 
156 
 
 
Book Chapters  
 
Genetics of dilated cardiomyopathy: Risk of conduction defects and sudden cardiac 
death 
Samer Arnous, Petros Syrris, Srijita Sen-Chowdhry, William J.McKenna 
Cardiac Electrophysiology clinics 2(2010) 599-609 
 
Cell base regenerative therapy 
Mozid A, Arnous S, Lovell M, Mathur A. 
EuroPCR Textbook of Interventional Cardiology 2012 : Chapter 3.49 
 
 
Aknowledgements 
I would like to express my sincere gratitude to my supervisor Professor Anthony  
Mathur for his continuous support of my MD research project. I would like to express my special 
appreciation to Professor William McKenna for encouraging my research and allowing me to 
grow as a research scientist. I would like to thank them for their motivation, enthusiasm, and 
immense knowledge, I would also like to thank my colleagues Catherine, Patricia, Jessry and 
Abdul at the London Chest hospital. All of you have been there to support me when I recruited 
patients and collected data for my MD thesis 
A special thanks to my family. Words cannot express how grateful I am to my mother and father, 
for all of the sacrifices that you’ve made on my behalf. 
Especially, I would like to give my special thanks to my beloved wife Jacqueline who 
has always been my support and whose patient love enabled me to complete this work. 
